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OBJECTIVE: Most drug use screening measures rely on and are validated against self-report. 
Fear of negative consequences often promotes denial of drug use. For pregnant women, social 
stigma and fear of legal consequences make underreporting of drug use even more likely. An 
indirect screener that could effectively identify pregnant women at risk for illicit drug use 
without reliance on disclosure would be clinically significant. The purpose of the current study 
was to develop and validate an indirect measure of prenatal drug use by comparing correlates of 
prenatal drug use to urinalysis results. METHOD: Pregnant women attending an OB 
appointment at the VCUHS Women’s Health Clinic were recruited and consented to participate 
in an anonymous, two-phase study. In Phase 1, women completed a 20-minute computerized 
assessment which included a true/false index of items known to tap behavioral, medical, 
 psychological, experiential and demographic correlates of drug abuse and dependence. In Phase 
2, participants were asked to provide a urine sample for drug testing. Women received a $20 gift 
card after they participated in each phase. RESULTS: Two hundred and thirty-one women 
completed both Phase 1 and 2 (94% completion rate). Participants were primarily African-
American (66%), single (75%) and receiving public assistance (70%). Urinalysis revealed that 
16% of the sample tested positive for recent drug use, while only 5% of women self-reported 
past month drug use. After examining the univariate and multivariate relationships between each 
indirect item and drug status (i.e., positive or negative urinalysis), six indirect items were chosen 
to comprise the Wayne Indirect Drug Use Screener-Pregnancy (WIDUS-P). Cross-validation 
analyses resulted in a sensitivity of .90, specificity of .75, and AUC of .85. In comparison to 
direct screening approaches, the WIDUS-P was superior in identifying pregnant women who had 
used drugs recently. CONCLUSIONS: Findings support the use of an indirect screening tool to 
identify prenatal drug use, especially over currently-used direct methods. Such a measure could 
easily be implemented into regular clinic practice and result in more cost-effective and better 
identification of prenatal drug use.  
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Indirect Screening: Enhancing Identification of Illicit Drug Use during Pregnancy 
Statement of the Problem 
Drug use is common in today’s society. A 2008 national survey found that almost one-
tenth of study participants reported recent use of illicit drugs (SAMSHA, 2009). Although men 
used illicit drugs at a higher rate than women (9.9% versus 6.3%), the rate of drug use among 
women increased from 2007 to 2008 but remained stable for men. During pregnancy, the 
majority of drug-using women tend to abstain from substance use (SAMHSA, 2009; Ebrahim & 
Gfroerer, 2003), however a proportion of drug-using women continue to use during the prenatal 
period (Bailey, Hill, Hawkins, Catalano, & Abbott, 2008). This rate, which ranges from 5-14% 
depending on the study, is significant given the numerous negative consequences associated with 
prenatal drug use for both mother and offspring (SAMSHA, 2009; Chasnoff, Landress, & 
Barrett, 1990; Huestis & Choo, 2002). Unfortunately, current prevalence rates of prenatal drug 
use are likely underestimations because drug use is frequently underreported (Magura & Kang, 
1996). Women face social stigma and negative consequences (e.g., loss of custody, legal 
charges) when they report prenatal drug use so it is not surprising that they minimize or deny 
using (Ondersma, Malcoe, & Simpson, 2000; Ondersma, Simpson, Brestan, & Ward, 2001; 
Lester, El Sohly, Wright, Smerigilio, Verter, Bauer, et al., 2001).  
Pregnancy has often been viewed as a “window of opportunity” as drug using women 
may be more motivated to reduce or eliminate use for the sake of the unborn baby (Daley, 
Argeriou & McCarty, 1998). Some women are able to do this on their own, while others may 
need assistance (Ebrahim & Gfroerer, 2003). Pregnancy is therefore an ideal time for screening 
and intervention, creating opportunities to positively impact public health. Unfortunately, 
prenatal drug screening often does not occur because of such barriers as lack of provider time 
and discomfort (Chasnoff, Neuman, Thornton, & Callaghan, 2001; Yarnall, Pollack, Ostbye, 
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Krause, Michener, 2003). Even if screening does occur, current screening methods fall short in 
adequately detecting prenatal drug use. Screening measures rely extensively on self-report, 
despite the documented issue of underreporting, and may lack utility in prenatal populations 
(Skinner, 1982; Midank et al., 1998; Chasnoff et al., 2005). Prenatal care providers often do not 
universally screen patients and face other barriers to identifying at-risk women (Chasnoff et al., 
2001; Anthony et al., 2010). Biological methods, while not limited by self-report bias, are less 
useful because of their cost and level of invasiveness. The consequence of these limitations is 
that prenatal drug use is often not identified at what would be a key time for intervention. New 
strategies are needed to more accurately identify drug use during pregnancy.  
Overall, the present study sought to compare different screening methods to a biological 
measure of prenatal drug use. Specifically, the purpose of this study was to develop and validate 
an indirect measure of drug use; one that would identify pregnant women who were continuing 
to use drugs, regardless of their willingness to disclose such use. The research built upon the 
recent work of Drs. Ondersma and Svikis who created the Wayne Indirect Drug Use Screener 
(WIDUS; Ondersma, Svikis, Grekin, Lam, & Connors, 2009), developed to identify post-partum 
women at risk for drug use during pregnancy.  
Review of the Literature 
In the following sections, I will introduce the issues of prenatal drug use and 
underreporting. In doing so, I will present research on prevalence rates of drug use in the general 
population and during pregnancy, factors commonly associated with drug use during pregnancy 
and maternal, fetal, and infant consequences of prenatal drug use. Then, I will describe both 
direct and indirect methods for detecting drug use during pregnancy, such as standardized 
screening measures and biological measures, and also highlight the limitations of these 
approaches. Next, I will elaborate on a recent study that utilizes an indirect method for 
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identifying prenatal drug use (i.e., the WIDUS) in order to provide a foundation for the current 
study. Finally, I will conclude with a discussion of the current study’s aims and hypotheses. 
Drug Use Prevalence  
 General population. Substance use is common in the general U.S. population. In a 
recent Substance Abuse and Mental Health Services Administration (SAMHSA) National 
Survey on Drug Use and Health (NSDUH), a representative sample of individuals ages 12 and 
older (N = 68,000) was interviewed about recent (past 30 days) and lifetime use of alcohol and 
other drugs. More than half of the sample (52%) reported consuming alcohol (beer, wine, liquor) 
in the 30 days prior to completing the interview. Almost a quarter (23%) reported binge drinking, 
defined as having five or more drinks on the same occasion on at least one day in the past 30 
days. Heavy drinking or having five or more drinks on the same occasion on at least five days in 
the past month was reported by about 7% of respondents.  Current (past 30 days) use of a 
tobacco product was also common, with over a quarter of respondents reporting use.  
In this SAMHSA survey, “illicit drug use” focused on marijuana, cocaine, heroin, 
hallucinogens, and inhalants as well as nonmedical use of prescription-type pain relievers, 
tranquilizers, stimulants, and sedatives. Approximately 8% of the sample and 6% of female 
participants reported recent use of at least one illicit drug. The most common drug used was 
marijuana and was reported by three-quarters of current drug users and was commonly the only 
drug used (57% of marijuana-users used only marijuana; SAMSHA, 2009). Marijuana was also 
the most frequently used drug among women (4.4% of women reported using marijuana). After 
marijuana, non-medically-used drugs were most commonly used (2.5% of the total samplep), 
followed by crack/cocaine (0.7%) and hallucinogens (0.4%; SAMSHA, 2009). 
 While not all individuals who use substances go on to develop or currently have a 
substance use disorder (SUD), a significant proportion of them do. Results from the same 
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NSDUH 2008 survey, indicated that almost 9% of respondents met Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria for alcohol 
and/or illicit drug abuse or dependence. Of these individuals, almost a third met criteria for illicit 
drug abuse or dependence, either in combination with alcohol abuse or dependence or alone. The 
rate of SUD for men was twice as high as the rate for women (12% versus 6%; SAMSHA, 
2009).  
Underreporting drug use. Prevalence rates of illicit drug use rely extensively on 
individual’s self-report, as often only one method of data collection is used (i.e., paper-and-
pencil questionnaire, interview). Individuals’ disclosure of substance use is influenced by their 
perceptions of social desirability. If they perceive that disclosure will be viewed negatively and 
may result in negative consequences, they may underreport or minimize their drug use. Drug use 
is often considered a sensitive behavior and especially given its illicit nature, individuals may be 
uncomfortable admitting use (Fendrich, 2005). Individuals may also be more hesitant to admit 
use of certain types of drugs, for instance, “harder” drugs (e.g., cocaine, amphetamine, and 
heroin) that carry a much (remove) stronger stigma than marijuana (Weir, Stark, Flemming, He, 
& Tesselaar, 1998). Consequently, self-reported drug use may not be a valid representation of an 
individual’s actual use.  
Biased self-reported drug use is problematic. When individuals distort their drug use it 
leads to inaccurate prevalence rates, which may in turn negatively impact screening and 
intervention efforts, as well as jeopardize the legitimacy of study conclusions (Macleod, 
Hickman, & Smith, 2005). The validity of self-reported drug use has been examined by 
comparing self-report to one or more biological measures of drug use (e.g., urinalysis, hair 
analysis, meconium testing). Magura and Kang (1996) conducted a meta-analysis of 24 studies 
involving self-report and biological measures of drug use in various high risk populations (e.g., 
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individuals involved in the legal system, psychiatric inpatients, post-partum women referred to 
drug treatment). Results indicated significant underreporting of self-reported drug use. While 
underreporting may be expected in high-risk populations given the potential for negative 
consequences of reporting drug use (e.g., legal charges), research has also provided support for 
underreporting in general populations (Fendrich, Johnson, Wislar, Hubbell, & Spiehler, 2004; 
Ledgerwood, Goldbeger, Risk, Lewis, & Price, 2008). In a random sampling of households in 
Chicago (N = 627), biological testing revealed higher rates of heroin and cocaine use than self-
report estimated. Of those testing positive by biological measures (i.e., a positive hair, urine, or 
saliva screen), only a quarter of individuals self-disclosed past year cocaine use and only one-
fifth disclosed past year heroin use. Interestingly, most individuals (78%) testing positive for 
marijuana reported use in the past year, possibly reflecting the idea that marijuana is a less-
stigmatized drug. Additionally, Fendrich and colleagues (2004) found that participants were 
more willing to disclose lifetime drug use than recent use (i.e., past month, past year), suggesting 
that lifetime drug use prevalence rates may be a more valid measure of drug use. Together, this 
research underscores the need to acknowledge the impact of underreporting on rates of self-
reported drug use.  
Pregnant women. Although many women reduce or stop substance use during 
pregnancy (SAMHSA, 2009; Ebrahim & Gfroerer, 2003), a significant proportion continue to 
use substances during the prenatal period (Bailey, Hill, Hawkins, Catalano, & Abbott, 2008). 
According to recent epidemiological data (2008 NSDUH), of pregnant women interviewed, ages 
15 to 44 years, 11% reported current (past month) alcohol use, 4.5% reported binge drinking 
(five or more drinks on one occasion) at least one day in the past month, and 0.8% reported 
heavy drinking (having five or more drinks on one occasion on at least 5 days in the past month). 
Cigarette smoking was more common than alcohol consumption among pregnant women: 16% 
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of respondents reported smoking at least one cigarette in the month prior to being interviewed. 
Rates of drug use were lower with 5% of pregnant women reporting use of illicit drug in the past 
month. Although the NSDUH did not break down prevalence of prenatal illicit drug use by type 
of drug used, marijuana was the most commonly used drug by women of childbearing age 
(SAMSHA, 2009). Research using an earlier version of the NSDUH survey also confirms this 
finding (Ebrahim & Gfroerer, 2003). Overall, in considering NSDUH data, it is important to 
recognize that these are conservative estimates of prevalence as the interviews focused only on 
the past 30 days rather than the entire prenatal period.  
Other studies focusing on specific samples (i.e., pregnant and postpartum women) and 
utilizing a range of methodologies (i.e., self-report, biological testing, review of hospital records) 
have found higher prevalence rates of prenatal substance use, specifically illicit drug use. Based 
on a review of hospital records of all births occurring in a county hospital in San Francisco 
during a 4-year period (July 1995-June 1999; N = 5940), 7% were determined to be drug-
exposed. Classification was based on maternal self-report of drug use, positive toxicology 
screens during pregnancy, and/or positive toxicology screens in the newborn (Wolfe, Guydish, 
Santos, Delucchi, & Gleghorn, 2007). Additional research utilizing toxicology screens at 
delivery have documented even higher rates of prenatal illicit drug use (14%; Chasnoff, 
Landress, & Barrett, 1990; Vega, Kolody, Hwang, & Noble, 1993). 
Underreporting in pregnant women. Prevalence rates of illicit drug use during 
pregnancy likely differ given the variability in methodologies used to detect use (e.g., interview, 
questionnaire, biological testing of mother and/or infant), which is discussed in a later section, 
and the types of populations studied (e.g., national, pregnant vs. postpartum, patients attending 
prenatal care, treatment-seeking). In addition, the high-risk nature of prenatal drug use may also 
lead women to underreport their use, making it difficult to obtain accurate prevalence rates 
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(Huang & Reid, 2006). Women who use drugs during pregnancy face social and legal 
consequences, including social stigma, child protective services involvement, and loss of 
custody, which leads them to underreport or minimize their drug use (Ondersma et al., 2000, 
2001). Their fears of negative consequences are not unjustified. In South Carolina, child 
protection laws include “viable fetuses” and thus pregnant women can be criminally prosecuted 
with such charges as child abuse/endangerment and/or illegal drug delivery to a minor. In 1989, 
the Medical University of South Carolina adopted policies which, in cooperation with a local 
prosecutor, selectively screened urine samples from medically indigent obstetric patients for 
cocaine metabolites. Those who screened positive were taken to the police, who then arrested the 
pregnant women on charges of possession of an illegal drug and either delivery of drugs to a 
minor and/or child abuse (Harris & Paltrow, 2003). 
Not surprising given these consequences, there is often discrepancy between self-report 
and biological measures of prenatal drug use. In a large, multi-site study of in utero cocaine 
and/or opiate exposure, rates of maternal self-report of prenatal drug use differed from rates of 
positive meconium analysis (Lester et al., 2001). Over 8,500 women were recruited shortly after 
delivery from four sites, varying in race, ethnicity, social class, and geographic region. Based on 
a maternal interview of past and current substance use, 661 (7.5% of the sample) women self-
reported prenatal cocaine and/or opiate use. However, testing of infant meconium and 
subsequent confirmation of positive screens identified an additional 254 drug-using mothers 
(2.9% of the sample) who denied prenatal drug use. Therefore, based on a combination of 
maternal self-report and meconium assays, 10.7% of all women used cocaine and/or opiates 
during their pregnancy. Earlier studies utilizing large samples of pregnant women have also 
noted discrepancies between self-report and toxicology screens (Frank, Zuckerman, Amaro, 
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Aboagye, Bauchner, Cabral, et al., 1988, Ostrea, Brady, Gause, Raymundo, & Stevens, 1992, 
NIDA, 1996).  
Drug Use and Pregnancy 
 Patterns of abstinence during pregnancy. As stated earlier, most women reduce their 
use of illicit drugs during pregnancy, either by abstaining completely or decreasing the frequency 
and/or quantity of their use (Ebrahim & Gfroerer, 2003). In addition, pregnant women may 
engage in other harm reduction approaches, such as switching to a less potent type of drug (e.g., 
from hashish to marijuana; el Marroun, Tiemieier, Jaddoe, Hofman, Mackenbach, Steegers, et 
al., et al., 2008). Data from the 1996-1998 National Household Survey on Drug Abuse (NHSDA; 
now known as the NSDUH), suggests that cessation does not occur immediately after women 
realize they are pregnant, but rather, during the third trimester most drug-using women report 
abstinence. The proportion of drug-using women reporting abstinence increased by trimester: 
28% were abstinent in their first trimester, 76% in their second trimester, and 93% in their third 
trimester. The remaining 7% of drug-using pregnant women continued illicit drug use during 
their third trimester. These statistics exemplify that although a small, but meaningful 
nonetheless, percentage of women continued drug use throughout pregnancy; almost a quarter of 
all drug-using women did not ultimately abstain until late in their pregnancy. 
 Frequency of drug use during pregnancy. When women continue using drugs into 
their pregnancy they tend to be frequent users. In a study of prenatal care patients attending 
urban healthcare centers in Minnesota (N = 1492), women who reported drug use at their first 
prenatal visit typically reported weekly or daily use of illicit drugs, as opposed to rare or monthly 
use (Harrison & Sidebottom; 2009). Researchers in the Netherlands (el Marroun et al., 2008) 
found similar results in their population-based study of pregnant women (N = 7531). Women 
who self-reported prenatal cannabis use (the drug of interest in this study) were most often 
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frequent users (80% used daily or weekly). Women who did not report prenatal use were likely 
monthly users. Additionally, pregnant women with a history of cannabis dependence were 
almost three times more likely to use prenatally (OR = 2.77, p < .001) than women with no 
history. Together, these findings of frequent use highlight the dependent nature of drug use 
during pregnancy and the difficulty of abstaining.  
Patterns of substance use. Not only does the frequency of substance use change during 
pregnancy, patterns in the type of substance used from pre-pregnancy to pregnancy may also 
differ. This has been shown specifically among low-income populations. Harrison and 
Sidebottom (2009) interviewed women attending their first prenatal care appointment (N = 
1,492) about their pre-pregnancy and prenatal (use that occurred after a woman found out she 
was pregnant) use of substances. The majority of participants were non-Caucasian (43.7% 
African American), young (mean age = 22.6 years), and low-income (90% received services 
through Medicaid or a state-funded program). Pre-pregnancy (12 months prior to pregnancy) 
substance use rates indicated that alcohol use was almost twice as common as drug use (41.1% 
vs. 24%). Interestingly, prenatal use showed the opposite pattern: almost twice as many women 
reported recent illicit drug use as recent alcohol use (10.7% vs. 5.6%). More specifically, drug 
use alone, as opposed to alcohol use alone or concurrent alcohol and drug use, was the most 
common substance use pattern reported during pregnancy. Further, the rate of women continuing 
substance use after they discovered they were pregnant was higher for drugs than alcohol (44% 
vs. 13%). In a smaller sample of prenatal patients (N = 130) with comparable demographics, the 
same pattern was true: women tended to report prenatal marijuana use more often than alcohol 
use (17% vs. 7%; Jesse, Graham, & Swanson, 2006). Overall, these findings underscore the need 
to address illicit drug use during pregnancy. Moreover, as with all self-reported rates, it is 
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important to consider the possibility that these percentages may be even higher because of 
underreporting.  
Factors associated with prenatal drug use. In an attempt to improve screening and 
identification of drug-using pregnant in prenatal care clinics, a growing body of research has 
examined factors associated with prenatal drug use. Unfortunately, the majority of these studies 
relied on women’s self-reported drug use to identify risk factors. As previously mentioned, this 
reliance on self-report is problematic given the frequency of underreporting by pregnant women. 
Nonetheless, the research is still informative as a first step towards better identification of 
prenatal drug use.  
Researchers have utilized both nationally representative and convenience (e.g., 
university-based obstetrics clinic, county hospitals) samples of pregnant women to identify 
correlates of drug use. A variety of factors have been examined, including demographic, social, 
psychological, experiential and pregnancy-related factors (Havens, Simmons, Shannong, & 
Hansen, 2009; Ebrahim & Gfroerer, 2003; Marcenko & Spence, 1995; Kelly, Zatzick, & Anders, 
2001; Horrigan, Schroeder, & Schaffer, 2000; Jesse et al., 2006).  
While studies have used different methodologies, common correlates of prenatal drug use 
have been identified. Demographically, pregnant drug-using women are more likely than non-
users to be unmarried (Havens et al., 2009; el Marroun et al., 2008; Wolfe et al., 2007; Huang & 
Reid, 2006; Ebrahim & Gfroerer, 2003), older (Harrison & Sidebottom, 2009), unemployed or 
never worked (Havens et al., 2009; Huang & Reid, 2006), receiving public assistance (Huang, & 
Reid, 2006; NIDA, 1996) and have less education (Ebrahim & Gfroerer, 2003). Prenatal drug-
users are also more likely to be experiencing current psychopathology, including depression, 
anxiety and suicidality (Havens et al., 2009; Jesse et al., 2006; Chasnoff, Neuman, Thornton, & 
Callaghan, 2001; Horrigan et al., 2000). They also often live with another adult who uses illicit 
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substances, have a family member with a drug or alcohol problem (Chasnoff et al., 2001; 
Marcenko  & Spence, 1995), and have experienced some form of abuse and/or childhood trauma  
in their lifetime (Horrigan et al., 2000; el Marroun et al., 2008; Marcenko & Spence, 1995). 
Delinquent behavior (i.e., having ever been arrested or having a criminal record) was also found 
to be a significant predictor of prenatal drug use (el Marroun et al., 2008). Additionally, 
women’s past and current substance use may be a useful indicator of current drug use.  Pre-
pregnancy and current cigarette smoking and alcohol use (Harrison & Sidebottom, 2009; Svikis, 
Henningfield, Gazaway, Huggins, Sosnow, Hranicka et al., 1997; Chasnoff et al., 2001; el 
Marroun et al., 2008), as well as pre-pregnancy drug use (Harrison & Sidebottom, 2009), have 
been found to be significantly associated with prenatal drug use.  
Research has also demonstrated associations between prenatal drug use and factors 
associated with low socio-economic status, including lack of transportation (Harrison & 
Sidebottom, 2009), housing instability (Chasnoff et al., 2001), and food insecurity (Harrison & 
Sidebottom, 2009). Some studies also suggest an association between prenatal drug use and 
sexually transmitted diseases (Horrigan et al., 2000; Berenson, Wilkinson, & Lopez, 1995). 
Additionally certain pregnancy-related factors, such as number of previous live births 
(Bendersky, Alessandri, Gilbert, & Lewis, 1996; Marcenko & Spence1995), history of preterm 
birth (Jesse et al., 2006; ), unintended pregnancy (el Marroun et al., 2008; Hunay & Reid, 2006), 
and seeking prenatal care later in pregnancy (Marcenko & Spence, 1995) have been associated 
with prenatal drug use.   However, the correlates of age and previous live births/number of 
children are confounded by the length of time a woman has used drugs and therefore, may act as 
a proxy for substance use disorder chronicity (Johnson, McCarter, & Ferencz, 1987). Lastly, 
women who used drugs during pregnancy compared to those who did not more often reported 
that the father of their baby also used drugs (el Marroun et al., 2008). 
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In utero effects of illicit drug use. When a pregnant woman consumes drugs, the 
substance crosses the placenta thereby exposing the fetus. Consequently, in addition to the 
general health risks associated with drug use for the mother, prenatal drug use poses risk to the 
developing fetus. Prenatal exposure is associated with a variety of perinatal complications 
including higher rates of spontaneous abortion, stillbirth, placental insufficiency, eclampsia, 
gestational diabetes, fetal growth retardation, low birth weight and premature labor (Finnegan, 
1994; Kennare, Heard, & Chan, 2005; Burns, Mattick, & Cooke, 2006). Not surprising given 
these consequences, drug-exposed infants tend to require more significant medical attention than 
non-exposed infants and are a greater socio-economic cost to society (Finnegan, 2000; Huestis & 
Choo, 2002). Prenatal drug exposure not only affects the fetus and infant, but can also impact the 
later cognitive and behavioral development of the child. While the specific long-term 
consequences vary by type of drug, prenatal exposure has been associated with lower IQ scores, 
increased behavioral problems, poor attention, impulsivity, impaired executive functioning and 
poor state control (Huestis & Choo, 2002; Behnke & Eyler, 1993).   
Research has shown that the link between prenatal drug use and negative outcomes is 
more complicated than direct causation. The effect of prenatal drug use on fetal and infant 
outcomes varies as a function of the type of drug use (i.e., type of drug, quantity, frequency, and 
duration) and individual characteristics (i.e., how an individual responds physiologically and 
psychologically to drugs). Environmental factors associated with prenatal drug use (e.g., low 
SES, poor prenatal care, poor nutrition) also contribute to negative outcomes, making it difficult 
to disentangle the unique effects of prenatal drug exposure (Anthony, Austin, & Cormier, 2010; 
El-Mohandes, Herman, Nabil El-Khorazaty, Katta, White, & Grylack, 2003).  In addition, poly-
substance use further complicates researchers’ ability to identify specific adverse consequences 
of specific drugs (Kandall, Doberczak, Jantunen, & Stein, 1999). Despite the many confounding 
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factors, there is still a great need for early detection and intervention of prenatal substance use in 
order to improve negative fetal/infant/child outcomes.  Early work by Chasnoff and colleagues 
(1989) highlights this window of opportunity: drug-using women who become abstinent by their 
third trimester have been found to significantly reduce the risk of medical complications. 
Unique circumstances of pregnancy. Pregnancy is a unique time for identification and 
intervention of problematic substance use. Most women stop using substances while they are 
pregnant, but often return to drug use during the postpartum period (SAMSHA, 2009; Ebrahim 
& Groerer, 2003). For those women who continue using into and throughout their pregnancy, 
their use of illicit drugs may be considered problematic and may even reflect addictive behavior 
(el Marroun et al., 2008). It is well known that most individuals with a substance use disorder do 
not seek treatment (SAMSHA, 2005). Thus, during pregnancy, when women are accessing 
health services more regularly than if they were not pregnant, is an ideal time to detect 
problematic drug use and to intervene. Motivation to seek help may be greater during this time 
because of women’s concerns about the health of their fetus (Grella, 1999), their own health 
(Gehshan, 1995) and fear of negative consequences (e.g., the legal implications of testing 
positive at delivery; Howell & Chasnoff, 1999). In a retrospective study utilizing county hospital 
and drug treatment service records, Wolfe and colleagues’ (2007) results support the notion of 
increased motivation during pregnancy. They found that significantly more women engaged in 
some form of drug treatment (i.e., outpatient, residential, methadone maintenance, or 
detoxification) during or after delivery than they did one year prior to becoming pregnant. 
Further, during pregnancy, substance-using women have the opportunity to reduce the harm to 
their fetus by quitting or cutting down whereas after delivery that window of opportunity expires. 
Although pregnancy is an ideal time for intervention, many drug-using women are not identified 
by their prenatal care providers, resulting in missed opportunity. Consequently, the ability to 
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refer and engage drug-using women in treatment rests on how well screening methods identify 
prenatal drug use. 
Detecting Drug Use during Pregnancy 
 A variety of methodologies, including biological testing and self-report questionnaires, 
have been developed to screen for problematic substance use. The purpose of screening is not to 
diagnose substance abuse or dependence, but rather to identify individuals who may be at-risk 
for these problems in order to facilitate referral for additional assessment and intervention. Given 
this purpose, priority is often given to sensitivity, the true positive rate of a screening tool, over 
specificity, the true negative rate. No matter the type of method used, accurate identification is 
extremely important as brief intervention and treatment efforts can only occur following proper 
identification of problematic drug use. Health care providers, particularly primary care providers, 
are in a unique position to screen for substance use problems because of their regular access to 
patients over time and because such questions are relevant to their health. In addition, because a 
woman’s obstetrician or gynecologist may function as her primary care physician (Klock, 2004), 
screening for prenatal drug use in OB/GYN clinics is ideal. During pregnancy, universal 
substance use screening at the first prenatal care visit (ACOG, 2006; Welch & Sokol, 1994), as 
well as throughout pregnancy (Svikis & Reid-Quinones, 2003) is recommended. When screening 
occurs, providers rely on a variety of methods. 
Biological screening methods. Drug screening or “drug testing” has become somewhat 
synonymous with biological methods, where a biological specimen (i.e., urine, hair, blood, 
saliva) is analyzed for the presence of different kinds of drugs and their metabolites. To identify 
prenatal drug use, both maternal and infant specimens can be analyzed. For instance, testing of 
infant meconium (i.e., the first stool of the newborn infant) post-delivery has been used to 
determine whether a woman used substances during her pregnancy (Bessa, Mitsuhiro, Chalem, 
15 
 
Barros, Guinsburg, & Laranjeira, 2010). Screening for illicit drugs often consists of an initial test 
using an immunoassay to determine whether or not a drug or its metabolite is present and then 
confirmatory testing that is qualitatively different from the initial test (e.g., chromatography/mass 
spectrometry) is conducted. The Substance Abuse and Mental Health Services Administration 
(SAMSA) established drug-specific cut-off points to standardize the results of drug testing. 
Methods vary with respect to their window of drug detection, the amount of time after ingestion 
during which the substance can be detected, whether results are qualitative (positive or negative 
for a particular drug) or quantitative (the level of the substance used) and their level of 
invasiveness. Consequently, each method has strengths and limitations (Wolff, Farrell, Marsden, 
Montiero, Ali, Welch, et al., 1999). Unfortunately, biological screening is often used when a 
provider suspects a pregnant woman is using drugs, but denies such use (Svikis & Huggins, 
1996). 
 Urine testing. Urinanalysis is a well-accepted method for detecting drug use because 
urine samples are easy to collect in sufficient quantities necessary for testing. In addition, drugs 
and their metabolites are usually present in urine in high concentration. Relative to other 
methods, urinanlysis has a short window of detection (i.e., 1-3 days) for most drugs, with the 
exception of marijuana, and therefore only identifies recent drug users. Use of marijuana can be 
detected in urine for weeks after last use. Another drawback to urine screening is that the sample 
can be easily adulterated to produce a false negative; however, temperature and pH tests can be 
used to determine the authenticity of samples (Wolff et al., 1999).  
 Hair testing. Hair analysis is another biological method to detect drug use and provides a 
“retrospective calendar” of use (Kintz, Villain, & Cirimele, 2006). Hair grows approximately one 
cm/month and so different sections of hair can be analyzed to create a timeline of use during 
pregnancy. Thus, hair analysis is considered advantageous over urinalysis because of its longer 
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window of detection. Research has also shown this method to have excellent sensitivity in 
detecting perinatal drug use (Ostrea, Knapp, Tannenbaurm, Ostrea, Romero, Salari, et al., 2001).  
However, this method is not without limitations. Although collecting a hair sample may be less 
invasive than collecting urine or blood, some women may be opposed to providing a hair sample 
because of cosmetic concerns or taboos (Eyler, Behnke, Wobie, Garvin, & Tebett, 2005). In 
addition, the results of hair analysis can be affected by individual and racial differences (i.e., hair 
color and texture), with coarser, darker hair incorporating more of a drug than thinner, lighter 
hair (Ebrahim & Gfroerer, 2003). Chemical processing (i.e., coloring, bleaching, straightening), 
and external exposure to drugs (e.g., hair tests positive for marijuana because of passive 
exposure to smoke rather than active ingestion) also impact test results.  
 Blood testing. Although drug testing blood samples is useful quantitatively, it is also a 
very invasive procedure which requires trained personnel and special handling procedures. 
Further, it may not be as useful as urine testing because most illicit substances leave the blood 
within a few hours of use and concentrations fall below threshold levels of detection (Wolff et 
al., 1999). These drawbacks limit the utility of blood testing as a screening tool in pregnant 
women. 
 Saliva testing. Collection of saliva is easy and less invasive than collecting other 
biological samples. The window of detection for oral fluid ranges from five to 48 hours and is 
typically shorter than that of urine (Verstraete, 2004).  In a study of pregnant opiate-dependent 
women, saliva testing was a highly sensitive method for detecting opiate and cocaine use (Dams, 
Choo, Lambert, Jones, & Huestis, 2007). However, the authors acknowledge that rates of 
detection will vary by cut-off concentrations, type of collection device, and detection method 
used. Thus, while it is a promising alternative to more invasive methods, additional research is 
needed to standardize the collection and testing of oral fluid.  
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Infant specimen testing. Testing newborn’s hair, urine and meconium are additional 
methods to detect prenatal drug use. Drugs and their metabolites are believed to accumulate in 
meconium at about 18 weeks gestation, when it is first produced, allowing drug use in the second 
and third trimesters to be detected (Ostrea, et al., 1992). This method provides a longer window 
of detection over oral fluid and urine testing. In addition, drug and metabolite concentrations 
may be higher in meconium than urine (Ostrea, Brady, Parks, Asensio, & Naluz, 1989). Hair 
taken from an infant may offer a more pure calendar of a mother’s drug use than her own hair as 
it has not been subject to the same contaminants (e.g., chemical processing, external exposure to 
drugs). However, a newborn may not have enough hair to adequately test for exposure to drugs 
(Eyler et al., 2005). Urine testing may be a useful alternative; however, this method is still 
limited to only recent drug use by the mother.  
Summary of biological methods. A variety of biological specimens have been used to 
detect prenatal drug use, including urine, hair, blood, oral fluid, and meconium. As elaborated 
above, each method has strengths and limitations. For detecting prenatal drug use, no biological 
method has been identified as the “gold standard.”  Drug testing does help identify women who 
deny use; however it may not be a cost-effective approach (Eyler et al., 2005). Further, 
identifying prenatal drug use at delivery (i.e., by testing infant specimens) prevents the 
possibility of early intervention and reducing harm to the fetus/infant.  
Direct screening methods. While many screening tools have been developed to assess 
at-risk drinking, a lesser number of measures exist to detect illicit drug use and problems. 
Furthermore, many of the existing screeners for problematic drug were adapted from or patterned 
after alcohol screening tools (e.g., the word, “drinking,” was replaced with “drug use” in the 
Drug CAGE). To an even lesser extent have measures been developed for or validated on 
pregnant women. Most screeners are direct or face-valid (i.e., they ask specifically about 
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substance use and its consequences), rely on individuals’ self-report and are administered as 
paper-and-pencil questionnaires or brief interviews. Examples of specific direct to screen for 
prenatal drug use are described below. 
Drug CAGE. The Drug CAGE is a 4-item, yes/no questionnaire designed to detect 
problematic drug use by asking: 1) Have you ever felt you should cut down on your drug use?; 2) 
Have people annoyed you by criticizing your drug use?; 3) Have you ever felt bad or guilty 
about your drug use?; and 4) Have you ever used drugs first thing in the morning to steady your 
nerve?  The CAGE was originally developed to screen for problem drinking (Ewing, 1984) and 
has become a widely-used alcohol screening tool for a variety of populations (Bradley, Boyd-
Wickizer, Powell, & Burma, 1998; Bradley, Kiylahan, Daniel, Bush, McDonell, Fihn et al., 
2001; Satre, Knight, Dickson-Fuhrmann, & Jarvick, 2004; Williams, Horton, Samet, & Saitz, 
2007), including pregnant women (Russell, Martier, Sokol, Mudar, Bottoms, Jacobson et al., 
1994; Russell, Martier, Sokol, Mudar, Jacobson, and Jacobson, 1996). Additionally, the CAGE 
was adapted to assess general substance use (i.e., use of alcohol and/or drugs; Brown & Rounds, 
1995) and also drug use (Midanik, Zahnd, & Klein, 1998; Kelly et al., 2001). A positive response 
to at least one of questions signifies at-risk substance use (Bradley, Kivlahan, Bush, McDonell, 
& Fihn, 2001). 
Midanik and colleagues (1998) modified the CAGE for use as a prenatal drug screener in 
a racially diverse sample of pregnant women (N = 1147) recruited from non-medical settings 
(e.g., community organizations and social service agencies). They argued that the open 
timeframe (i.e., have you ever) limits the CAGE’s utility in pregnant women and so they 
restricted questions to the 12 months prior to pregnancy recognition. This adapted version of the 
Drug CAGE was validated against self-reported drug use, which was broken down into lighter 
drugs (i.e., uppers, diet pills, stimulants, tranquilizers, sleeping pills, valium, morphine, other 
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pain killers, sedatives), heavier drugs (i.e., cocaine/crack, methamphetamine, ice, heroin, 
methadone, speedballs) and marijuana/hashish, during the same time period. Sensitivity or the 
proportion of self-reported drug users who screened positive on the CAGE and specificity, the 
proportion of self-reported non-users who screened negative on the CAGE, of this adapted 
measure were evaluated. Results indicated very low sensitivity for lighter drugs and marijuana 
and higher sensitivity for harder drugs. Specificity was high no matter the type of drug used. 
Thus, for lighter drugs and marijuana, the Drug CAGE does not appear to be an effective 
screening tool for pregnant women. However, an argument can be made to support the measure’s 
utility in identifying women at risk for heavier drug use. According to ROC analysis, a cut-off of 
1 was found to be the optimal score to optimize both sensitivity and specificity. However, when 
sensitivity is valued over specificity, a cut-point of 3 was recommended to identify harder 
prenatal drug use.  
While this research is informative, Midanik and colleagues’ (1998) results must be 
viewed in consideration of a major limitation: the study relied completely on pregnant women’s 
self-reported drug use to validate the modified CAGE. As previously described, underreporting 
is common among pregnant women. Thus, it is imperative for future research examining the 
utility of the drug CAGE as a screening tool for prenatal drug use to employ drug use criterions 
that are less vulnerable to self-report bias (i.e., biological measures).  
DAST. The Drug Abuse Screening Test (Skinner, 1982) is another commonly-used 
screening tool for problematic drug use. The self-administered questionnaire was developed by 
adapting items from the Michigan Alcoholism Screening Test (MAST; Selzer, 1971) and exists 
in three versions (10-, 20- and 28-items). The yes/no items measure consequences of drug use 
and other factors associated with drug use disorders.  The measure in varying forms has been 
widely used in a number of populations, including individuals with known drug problems 
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(Gavin, Ross, & Skinner, 1989; Bohn, Babor, & Kranzler, 1991; Kush & Sowers, 1996), 
psychiatric patients (Staley & El-Guebaly, 1990), union members (El-Bassel, Schilling, Schinke, 
Orlandi, Wei-Huei, & Back, 1997) and female offenders (Salstone, Halliwell, & Hayslip, 1994).  
In a review of the DAST’s psychometric properties (Yudko, Lozhkina, & Fouts, 2007), 
the measure showed good internal consistency (α ranged from .74- .94) and test-retest reliability 
(r ranged from .71- .85). Evidence was also found to support the criterion and construct validity 
of the DAST. Additionally, the measure’s discriminative validity (i.e., its ability to separate 
individuals with and without drug use disorders) was examined by comparing scores on the 
DAST against a criterion measure, either a psychiatric diagnosis of substance abuse or 
dependence or symptoms of the disorders. Overall, sensitivity and specificity was extremely 
variable and differed based on the population of interest, version, type of criterion (presence of a 
diagnosis or symptoms) and cutoff score used (Yudko et al., 2007). Interestingly, the DAST has 
only been compared to measures based on self-report (e.g., other screening instruments or a 
structured clinical interview).  
The DAST is a face-valid measure: if an individual does not want to be identified with 
drug problems, then he or she can easily provide responses that are not indicative of a problem. It 
is not surprising then that the DAST has been found to be negatively correlated with both social 
desirability (r = -.38, p < .001) and denial (r = -.28, p < .001; Skinner, 1982). In an employment 
setting, where negative consequences are possible, a stronger relationship was seen between 
DAST scores and social desirability (r = -.47; El-Bassel et al., 1997). Together, these results 
question the utility of the DAST with individuals who may be motivated to minimize or conceal 
drug use (e.g., in the workplace, criminal justice settings). Additional research with the DAST is 
needed in order to determine its usefulness in populations vulnerable to underreporting.  
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Drawbacks of the Drug CAGE and DAST. While the CAGE and the DAST have been 
commonly used, their application to pregnant women is still questionable. First, these measures 
have only been validated against self-reported criterions. In the study by Midanik and colleagues 
(1998) the criterion was self-disclosed drug use in the 12 months prior to pregnancy recognition. 
In the case of the DAST, a diagnosis of drug abuse or dependence, which is primarily based on 
self-report, was frequently used as the criterion for drug problems (Cocco & Carey, 1998; 
Maisto, Carey, Carey, Gordon, & Gleason, 2000). In these studies, self-report was validated 
against self-report. This is problematic given that self-report relies on individuals’ accuracy in 
reporting their own behavior and thus may be biased. Furthermore, the screening tools described 
above may also be inappropriate for pregnant women given that their purpose is to identify 
problematic drug use (i.e., drug use and associated problems that reach a diagnosable level). 
During pregnancy, any use of illicit drugs can be considered problematic given the possible 
negative effects on the fetus. Consequently, a woman’s drug use does not need to meet a 
diagnosable level in order for her to be at-risk and so she may be missed on a screening tool 
designed to detect problematic use (Anthony et al., 2007). 
The 4P’s Plus. The 4P’s Plus is a short, five-question screening tool administered by 
prenatal care providers to identify pregnant women in need of additional assessment and/or 
monitoring of their alcohol, tobacco, and/or illicit drug use (Chasnoff, McGourty, Bailey, 
Hutchins, Lightfoot, Pawson, et al., 2005). Questions ask women about their parents’ and 
partner’s  problems with alcohol and/or drugs, use of alcohol in the past and use of alcohol and 
cigarettes in the month prior to becoming pregnant. A woman is considered to have a “positive” 
screen if she admits use of alcohol or tobacco in the month before she knew she was pregnant. 
The 4P’s Plus is considered an effective and easy to administer tool to identify women at highest 
risk of prenatal substance use (Chasnoff et al., 2005).  
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Direct methods and self-report. The direct screening methods discussed above are face-
valid techniques that rely on self-report. Self-report is problematic because it is vulnerable to 
forgetting. Individuals may inaccurately recall the frequency, duration, and quantity of their drug 
use (Lester et al., 2001). Additionally, individuals can also easily deny or minimize their drug 
use if they do not want to be identified. Research has shown that individuals tend to underreport 
or minimize their substance use (Magura & Kang, 1996). As previously mentioned, this is not 
only true in the general population, but also among pregnant women (Frank et al., 1988, Ostrea 
et al., 1992, NIDA, 1996), whose disclosure of use carries significant legal and social 
implications (Derauf, Katz, & Easa, 2003; Markovic, Ness, Cefilli, Grisso, Stahmer, & Shaw, 
2000; Harrison, Haaga, & Richards, 1993).  
Translational issues with direct screening methods. While direct screening methods 
may be useful to a certain degree, there are other issues that impact the utility of direct prenatal 
drug screening. In addition to self-report bias, providers themselves can be a source of bias. 
Although ACOG recommends universal screening of all pregnant women, regardless of their 
social status, educational level, race, or ethnicity (ACOG, 2006), this does not necessarily always 
occur. Providers may selectively screen women based on their own biases (i.e., they may only 
ask the women who they think are using drugs during pregnancy). For instance, they may decide 
to screen on the basis of pregnancy complications, poor pregnancy outcomes or correlates of 
drug use, instead of screening universally (Weir et al., 1998).  
Chasnoff, Landress, and Barrett (1990) examined the rate of illicit drug use among all 
women seeking prenatal care at five public health clinics (n = 380) and 12 private obstetrical 
offices (n = 335) in Pinellas County, Florida, where reporting of known prenatal drug use is 
mandated by law. Prevalence rates of drug use were compared to providers’ post-delivery reports 
to health authorities of women who used drugs prenatally. The study found that providers were 
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10 times more likely to report African American women than Caucasian women to authorities 
even though their rates of drug use were similar. In addition, women of lower socio-economic 
status were more likely to be reported than women of higher SES. Sadly, similar racial and 
economic biases were also found in a more recent study of provider decisions to test for illicit 
prenatal drug use (Veda Kunins, Belline, Chazotte, & Du, 2007). Given these biases, it is not 
surprising that pregnant African American women and women of lower SES are more likely to 
underreport their drug use, especially under non-anonymous screening conditions (Chasnoff et 
al., 1990; Alvik, Haldorsen, & Lindemann, 2005). 
 In addition to provider bias, additional barriers prevent identification of women at-risk 
for prenatal drug use. Such obstacles include providers’ lack of knowledge and skill of how to 
screen effectively and intervene with positive screens (Chasnoff et al., 2001; Miller, Ornstein, 
Nietert, & Anton, 2004), time constraints (Yarnall et al., 2003) and lack of familiarity with 
resources and referral sources (McLellan, Lewis, O’Brien, & Kleber, 2000; Trude & Soddard, 
2003). In addition, providers may be deterred from asking women about their substance use 
because of the possible legal implications of a positive response or because they feel 
uncomfortable doing so and fear offending their patients (Anthony et al., 2010; Chasnoff et al., 
2001; Chavkin, 1990; Morse, Gehshan, & Hutchins, 1997). Regardless of the reason why health 
care providers are not universally screening prenatal care patients for substance use, the 
consequence is the same: women who use illicit drugs prenatally are, for the most part, “missed” 
at a critical time for intervention. 
Indirect methods. Given the limitations of current screening tools, efforts have been 
made to utilize indirect techniques for identifying substance abuse. Such instruments attempt to 
circumvent the issue of underreporting by avoiding obvious questions about substance use. 
Subscales on the Minnesota Multiphasic Personality Inventory- 2 (MMPI-2) and the Substance 
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Abuse Subtle Screening Inventory (SASSI-3; Miller & Lazowski, 1999) are examples of such 
indirect measures.  
MMPI-2 subscales. The MacAndrew Alcoholism Scale-Revised (MAC-R; MacAndrew, 
1965) and the Addiction Potential Scale (APS; Weed, Butcher, McKenna, & Ben-Porath, 1992) 
are two subtle scales designed to distinguish between individuals with substance use disorders 
and controls. Both scales were developed by identifying items that differentiated individuals with 
a known SUD (e.g., inpatients at a chemical-dependency program) from individuals with no 
SUD (e.g., psychiatric inpatients, individuals from the MMPI-2 normative sample). MMPI items 
included in these scales do not deal directly with substance use but rather reflect personality 
dimensions and life situations frequently endorsed by individuals with a SUD. For example, 
factor analysis of the APS revealed six factors: harmful habits, positive treatment attitudes, 
forthcoming, hypomania, risk taking, and passivity (Weed, Butcher, & Ben-Porath, 1995). 
Among treatment-seeking individuals, the APS was found to have poor sensitivity (.46-.64; 
Rouse, Butcher, & Miller, 1999; Stein, Graham, Ben-Porath, & McNulty, 1999). More recent 
research using a structured clinical interview as the gold standard found no clinical utility for the 
APS (Clements & Heintz, 2002). Similar to psychometric studies with direct measures, the “gold 
standard” was a self-report measure, so self-report was again validated against self-report. An 
additional limitation of MMPI scales is that development was limited to items already part of the 
MMPI-2; thus, many possible items of potential utility in predicting drug use among pregnant 
women (e.g., pregnancy-related variables) could not be considered.  
Substance Abuse Subtle Screening Inventory. The Substance Abuse Subtle Screening 
Inventory (SASSI-3; Miller & Lazowski, 1999) is a 93-item proprietary measure comprised of 
both indirect and direct items designed to screen for substance dependence. One scale is 
comprised of 67 true/false items that are both indirect (e.g., “I am rarely at a loss for words”) and 
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direct (e.g., “I have used alcohol or ‘pot’ too much or too often”). The authors recommend 
administering this scale first, before the second scale, which is composed of 26 Likert-scaled 
questions that ask directly about substance use and its negative consequences. The SASSI 
includes four clinical subscales (Face Valid Alcohol, Face Valid Other Drugs, Obvious 
Attributes, and Subtle Attributes), two defensiveness subscales (Defensiveness and Supplemental 
Addiction Measure) and either two or three supplementary subscales (Random Answer Pattern, 
Corrections, and Family Problems). Scores on the SASSI are interpreted according to decisions 
rules and thus individuals are classified as “high probability of having a substance dependence 
disorder” if their profile meets criteria for one of the conditions (e.g., above the 84th percentile 
on any two clinical subscales). Empirical evidence supporting the SASSI is weak. One peer-
reviewed study comparing scores on the measure to urinalysis data, found that the measure failed 
to identify 45% of pregnant women who tested positive for drugs (Horrigan & Piazza, 1999). 
Further, a recent review of the SASSI’s psychometric properties (N = 36 articles) “found no 
independent empirical evidence that the SASSI is more sensitive or accurate or less susceptible 
to falsification in screening for SUDs than simpler direct scales [e.g., CAGE, Michigan 
Alcoholism Screening Test, Alcohol Use Disorders Identification Test] available in the public 
domain” (Feldstein & Miller, 2007, p. 47). The authors of the review also concluded that it is 
unclear what the indirect scales are measuring: the indirect items purport to assess correlates of 
SUDs, although the nature of these traits is not clearly specified and have been found to change 
with treatment.  
Summary of indirect methods. Overall, existing measures that rely on subtle or indirect 
methods of identification (i.e., the subscales on the MMPI-2 and the SASSI, described above) do 
not appear to be well-suited for use as a screening tool for pregnant women in prenatal care 
settings. While an indirect methodology may limit socially desirable responding, clearly 
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additional research is needed to develop a more time- and cost-efficient screening tool to better 
detect prenatal drug use.  
New direction with an indirect method. In a recently completed project, Drs. Ondersma 
and Svikis examined indirect drug screening involving validation with objective measures of 
drug use in a sample of post-partum women at an urban, obstetric hospital in Detroit, Michigan. 
A checklist of indirect factors associated with drug use disorders, the Wayne Indirect Drug Use 
Screener (WIDUS; Ondersma et al., 2009) was validated against hair and urine analysis. This 
corroboration using biological testing was a key methodological advantage over previous efforts 
to identify an indirect measure.  
The WIDUS. The WIDUS is a true/false index of items known to tap correlates of drug 
abuse and dependence. The creation of this measure reflected Newcomb and Feliz-Ortiz’s (1992) 
epidemiological/cumulative stress and resiliency model which conceptualizes risk as multiply-
determined, emphasizing both protective and risk factors. In order to identify correlates of drug 
use, an extensive literature review was conducted by Dr. Ondersma and his colleagues. The 
domains sampled from correlational research included the following: (1) behavioral correlates, 
such as tobacco or alcohol use, emergency room use, gambling, fighting, promiscuity, criminal 
behavior, and less involvement in school, work, or religious activities; (2) medical correlates, 
such as chronic illness, sexually transmitted diseases, and dental problems; (3) psychological 
correlates, including depression, anxiety (particularly those associated with PTSD), 
neurobehavioral disinhibition in childhood (such as oppositional or conduct disorders), risk 
taking, sensation-seeking, and attitudes/expectancies consistent with drug use; (4) experiential 
correlates, such as having experienced trauma, childhood abuse, automobile accidents, blackouts, 
running away as a youth, time in foster care or group homes, interpersonal victimization, 
violence exposure, and poor parental bonding; and (5) demographic correlates, including being 
27 
 
younger, unemployed, unmarried, or a recipient of some form of public assistance. For a more 
complete list of correlates and their references, please see Appendix A. Protective factors in all 
of these areas, such as law abidance, religious involvement, self-acceptance, and positive 
relationships with parents (Newcomb & Felix-Ortiz, 1992), were also included along with risk 
factors in order to provide a more complete picture of overall risk.  
Items reflecting each drug use correlate and protective factor were generated and 
combined to form an initial item pool. A panel of experts, Dr. David Streiner, a statistician and 
psychometrician, Dr. Ralph Tarter, creator of the Drug Use Screening Inventory (DUSI) and Dr. 
Charles R. Schuster, a senior drug abuse researcher, reviewed the items. Following expert 
review, a small sample of post-partum women (N = 10), who had recently delivered at Hutzel 
Women’s Hospital in Detroit, Michigan, rated the initial item pool on the clarity, interpretation, 
and acceptability of each item. After incorporating this feedback into a finalized version, the 
127-item measure was administered via an audio-enhanced computer-assisted self-interview (A-
CASI) software program to a sample of 400 post-partum women recruited from their post-
delivery hospital rooms. The software relied on a three-dimensional cartoon character, Peedy the 
parrot, to provide instructions and guide the particpant through the questionnaire. Following 
completion of the WIDUS, hair and urine samples were collected. Data analysis identified a 
subsample of seven items that best predicted drug use (i.e., positive by urine and/or hair testing). 
These items are presented in Table 1.  
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Table 1 
 
WIDUS Items 
# Item 
1 I am currently married 
2 In the past year, I have been bothered by pain in my teeth or mouth 
3 I have smoked 100 cigarettes in my entire life 
4 There have been times in my life, for at least two weeks straight, where I 
felt like everything was an effort 
5 Most of my friends smoke cigarettes 
6 I get mad easily and feel a need to off some steam 
7 I often have trouble sleeping 
 
Dr. Ondersma’s study also involved an additional component that addresses what to do 
when women screen positive on the WIDUS. Women who screen positive on an indirect 
screener cannot be viewed as known drug users. Consequently, traditional methods of 
intervention would not apply. Dr. Ondersma and his colleagues developed an indirect, brief 
intervention software program designed to promote self-change or treatment-seeking among 
women who screen positive. The intervention is a single, 20-minute session that addresses 
substance use indirectly within topics of emotional health, healthy lifestyle and safety in and 
around the home. Therefore, the intervention is still relevant to women who are falsely identified 
as drug users by the WIDUS (i.e., false positives). 
 Overall, the development and validation of the WIDUS represents a significant effort to 
improve the identification prenatal drug use. Most importantly, this screening tool was developed 
and validated against non-self-report measures of drug use (i.e., urine and hair assays), unlike 
other commonly-used screeners which were validated against self-report. This measure was also 
developed within the context of anonymity and using ACASI technology, both of which have 
been shown to reduce underreporting (Durant, Carey, & Schroder, 2002; Newman et al., 2002). 
Finally, the WIDUS is an innocuous, indirect measure of drug use and thus likely to minimize 
the amount of underreporting present with direct screening tools.  
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Current Study 
The purpose of the current study was to develop and validate an indirect measure of drug 
use that can identify pregnant women who have a history of recent drug use, regardless of their 
willingness to disclose such use. The study built upon the work of Drs. Ondersma and Svikis in 
order to examine what indirect items best predicted drug use in this sample of pregnant women. 
Specifically, four questions were asked to guide this research:  
1) Are women in this population underreporting the incidence of prenatal drug use?  If 
so, what is the extent of the discrepancy between self-report and UDS? 
2) Do pregnancy-related variables contribute additional predictive validity to an 
existing indirect drug screening tool developed with postpartum women (i.e., the 
WIDUS)? 
3) Considering both prenatal and general drug use correlates, which items best predict 
recent drug use in this sample of pregnant women? 
4) How well do direct measures of drug use predict prenatal drug use (i.e., positive 
UDS) compared to indirect measures? 
Based on past research, the following hypotheses were made: Hypothesis 1) pregnant women 
will underreport recent drug use (i.e., prevalence rates of drug use will be higher according to 
urinalysis than direct self-report); Hypothesis 2) indirect screening tools will be a better predictor 
of recent drug use according to urine toxicology results than direct screening methods. 
Method 
Participants  
Participants were 231 pregnant women attending a return prenatal appointment at the 
VCUHS Women’s Health Clinic. Demographic characteristics for the sample are summarized in 
Table 2. Specifically, the sample was primarily African American (66%), single (75%) and 25 
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years of age or younger (61%; ages 18-25). The mean estimated gestational age (EGA) for the 
fetus, at time of assessment was 26.4 weeks (SD = 9.0), which is the beginning of the third 
trimester. Additional pregnancy-related statistics are presented in Table 3. 
Table 2 
 
Demographic characteristics N = 231 
Variable n % 
Age (years)   
18 - 21 73 32 
22 - 25 67 29 
26 - 29 43 19 
30 - 33 32 14 
34 - 37 12 5 
≥ 38 4 2 
Race/Ethnicity   
Black or African American 152 66 
White 55 24 
More than one race 12 5 
American Indian or Alaska Native 8 3 
Hispanic or Latino 4 2 
  
Marital status   
Married 59 25 
Education   
Completed high school or received GED 181 78 
Employment   
Working 20 hours or more per week 83 36 
Insurance/Support   
Have health insurance through an employer 80 35 
Receive some form of public assistance 162 70 
Relationship status   
None 42 18 
Yes, with the FoB 183 80 
Yes, but not with the FoB 5 2 
Contact with FoB   
Yes, current 215 94 
In the past only 15 6 
Do not know FoB well 0 0 
Note. FoB = Father of my baby. 
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Table 3 
 
Pregnancy characteristics N = 231 
Variables Mean (SD) or n Range or % 
EGA (weeks) 26.35 (9.0) 2, 40 
EGA at pregnancy recognitiona 6.48 (4.2) 1, 31 
EGA at first OB appointment 9.42 (4.8) 1, 27 
Parity   
Primigravida 67 29 
Total pregnancies (including current) 2.73 (1.9) 1, 8 
Live births 1.56 (1.5) 0, 8 
   
Pregnancy intention   
Wanted to be pregnant sooner 33 14 
Wanted to be pregnant then 52 23 
Wanted to be pregnant later 83 36 
Did not want to be pregnant then or in future 37 16 
Do not know 25 11 
Note. EGA = Estimated gestational age. 
aHow many weeks pregnant were you when you first thought you might be pregnant? 
 
 Inclusion Criteria:  To be eligible for the study, women had to be: at least 18 year of 
age, pregnant, and able to understand spoken English. In addition, women had to have completed 
at least one prenatal visit in the VCUHS OB clinic prior to study enrollment in order to exclude 
women who used drugs without knowledge of their pregnancy. 
 Exclusion Criteria: Women who were unable to provide informed consent due to 
cognitive impairment or a major psychiatric illness were ineligible for the study. 
Sampling Procedures 
 Participants were recruited from the VCUHS Women’s Health Clinic, which provides a 
wide variety of obstetric and gynecological services for women in the greater Richmond, 
Virginia area. Approximately 90 new obstetric patients are seen in the prenatal care clinics each 
month. Women were approached while waiting for their OB appointment in the clinic waiting 
room and screened for eligibility (please see Appendix B for Recruitment Script). If a woman 
was eligible, she was given a brief explanation of the two-phase project and potential to earn $40 
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in gift cards. Study procedures were approved by the VCU Institutional Review Board (protocol 
number HM12365) and the NIH NIDA Ethics Committee. 
Materials 
All study questionnaires, including the WIDUS-P development version, were 
administered via computer as opposed to paper-and-pencil or face-to-face interview methods. 
Women used headphones to hear each item and the various response options were read aloud as 
they appeared on the computer screen. The computerized test battery measures are described 
below in the order that they were administered. Order of administration was important for the 
generalizability of results and thus the indirect items of drug use had to be completed prior to the 
more direct measures of prenatal drug use risk.  
Wayne Indirect Drug Use Screener- Pregnancy (WIDUS-P). The WIDUS-P 
development version (please see Appendix C), consists of 86 items and contains 64 of the 127 
items from the development version of the WIDUS. Items from the WIDUS were selected for 
one of two reasons. Forty of the items were chosen because of their superior performance on 
selection criteria (e.g., endorsement rates, reading level, association with drug use, participant 
and expert ratings) in Dr. Ondersma’s analyses of 400 postpartum women. The item, “I smoked 
at least one cigarette during the last month of my pregnancy,” which was a top 40 item, was 
changed to “I smoked at least one cigarette the week before I learned I was pregnant” in order to 
make it applicable to a pregnant sample. Due to the difference in the nature of the samples (i.e., 
the WIDUS was developed using a sample of post-partum women whereas the current study will 
recruit pregnant women), additional items (i.e., 24 from the development version of the WIDUS) 
were added to capture domains potentially relevant to a sample of pregnant women.  In addition, 
based on a review of the literature focused on correlates of drug use during pregnancy (see 
section above), additional items were generated to include correlates not already addressed in the 
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top 40 WIDUS items or the additional 24 items retained from the WIDUS development version. 
Additional items included general pregnancy-related questions, such as estimated gestational age 
at first prenatal visit, pregnancy intention (i.e., intended, unwanted, mistimed, or ambivalent; 
Mohllajee, Curtis, Morrow, & Marchbanks, 2007), and types of maternal loss experienced (i.e., 
died during birth/stillborn, abortion, death during the first 4 months of pregnancy, death after the 
first 4 months of pregnancy).  
Drs. Ondersma and Svikis subsequently evaluated each item for its clarity and usefulness 
in identifying drug-using pregnant women within the VCUHS OB/Gyn clinic. Considerations 
were also made to ensure that items appropriately sampled relevant domains (e.g., exposure to 
violence was assessed using several items, rather than a single item), yet did not contribute 
unnecessarily to the length of the measure.  
Drug CAGE. The drug CAGE is a 4-item measure that asks questions about four 
problem domains: annoyance, cutting down, guilt, and eye-opener use. A “yes” response to one 
or more items was used to categorize participants as drug-positive according to this measure 
(Bradley et al., 2001).   
Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST; WHO 
ASSIST Working Group, 2002). The ASSIST was developed to detect substance use in 
primary and general medical settings. In Dr. Ondersma’s original WIDUS development study, 
the first two items of the ASSIST were included in the measure to screen for drug use in the most 
direct and parsimonious way possible. These same items were also included in the present study, 
as they ask whether participants have ever used marijuana, cocaine, opiates, or amphetamines in 
their lifetime as well as during three months prior to pregnancy recognition. The present study 
also added a third question which asked specifically about recent (last month) drug use via self-
report. 
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Drug Abuse Screening Test (DAST-10; Bohn et al., 1991). The DAST is a widely-
used, self-report questionnaire that measures consequences of drug use and other factors 
associated with drug use disorders. The cut-off score for the 10-item version is 3 (Skinner, 1982). 
The psychometric properties of the DAST have been supported in a number of studies (Yudko et 
al., 2007); however, as previously mentioned, the DAST’s utility as a screening tool in 
populations vulnerable to social desirability and denial (Skinner, 1982; El-Bassel et al., 1997) is 
of concern. Dr. Harvey Skinner provided his permission for use of the DAST in the present 
research study. 
Urine drug screening (UDS). Urine samples were obtained from all participants who 
agreed to participate in Phase 2 of data collection. Cups with embedded test strips on the cap 
(i.e., Reditest® RediCup® drug screen, 10 panel), were purchased from Redwood Toxicology 
Laboratory, a federally-certified supplier. Screens were performed by the main investigator and 
trained research assistants and provided only qualitative data (i.e., positive or negative) on 
methamphetamine, cocaine, marijuana, benzodiazepines, methadone, barbiturates, MDMA 
(ecstasy), opiates, PCP, and oxycodone use. With the exception of marijuana, urinalysis provides 
a window of detection between 24 and 48 hours. Detection of marijuana varies according to the 
extent of use; however detection can range from two to 14 days. For the gold standard criterion 
of drug use (i.e., urinalysis drug assay), a participant’s drug status was considered “drug 
positive” if she screened positive for methamphetamines, cocaine, marijuana, barbiturates, 
MDMA and/or PCP.   While evidence of benzodiazepine, methadone, opiate and/or oxycodone 
use via urinalysis drug testing might also demonstrate prenatal drug use, these categories of drug 
were not considered in the construction of the primary drug use variable because the positive 
screen could be the result of prescription (i.e., licit) use of these substances.   
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Design and Procedures 
 The primary goal of the study was measurement development and validation. A critical 
design component of this research, intended to protect the validity of findings, was that 
participation was completely anonymous. Participants were not required to provide their name or 
other identifying information to participate in the study (i.e., they were not required to sign a 
consent form). Such anonymity was important as it may have minimized the fear of negative 
consequences and stigma associated with self-reporting drug use or providing a positive urine 
sample. Consequently, anonymity may have encouraged greater rates of participation and more 
accurate responses on both indirect items and direct measures of drug use. 
Another important design consideration involved the use of sequential informed consent 
to protect the generalizability of the WIDUS-P. Generalizability depends on how closely future 
clinical applications of the WIDUS for pregnant women can be replicated. This meant that 
participants must not have initially known that they would be asked for permission to drug test 
their urine. If women were aware of the possibility of drug screening while answering questions, 
they may have responded differently than if they had no knowledge of the potential to be tested.  
In this situation, altered responding would have limited the use of the WIDUS in settings where 
drug does not routinely occur (e.g., prenatal care clinics). Therefore, a two phase consent 
procedure allowed for initial withholding of information necessary for valid measure 
development. Participants completed Phase 1, which involved completion of the computerized 
battery, before they learned about the existence of Phase 2 (collection of a urine sample). This 
procedure was critical to preserve the external validity of the WIDUS-P. 
Phase 1 procedures. Phase 1 concerned the administration of the computerized battery. 
Due to issues of validity previously mentioned, information about urine drug testing was 
withheld until after the participant completed the computerized battery. When a woman 
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expressed interest in the study, she was asked to come to the research space adjacent to the 6th 
floor Women’s Health clinic after her prenatal appointment. Once she arrived there, a research 
staff member informed her of study details (please see Appendix D, “Information Sheet #1”), 
including what kinds of questions will be asked, her rights as a participant, the anonymous and 
voluntary nature of the project (i.e., she will not be asked to give her name), her compensation 
for completing phase 1of a $20 gift card, and that phase 2 will be described to her after she has 
completed phase 1. Participants were assured that their information would not be shared with 
clinic staff. After the woman provided verbal consent to participate, the researcher introduced 
her to the tablet PC, instructed her to put on headphones, and begin the computer program. 
Headphones were used in order to protect participants’ privacy and to circumvent issues of 
literacy. The computer program, via an animated character (i.e., Peedy the parrot), instructed the 
participant how to use the computer and answer questions, and then introduced the questionnaire. 
Previous research utilizing this software and animated character has shown that women (N = 
+1000) found it easy to use and likeable (e.g., Ondersma, Chase, Svikis, & Schuster, 2005). 
Once the participant answered all computer questions, the program prompted the participant to 
tell the researcher she was finished. The researcher then entered an identification number for the 
participant so that the data could be linked to her urinalysis results. After the computerized 
assessment was complete, the research assistant gave the participant a $20 gift card. Total 
administration time for phase 1 was 20-25 minutes. 
Phase 2 procedures. After providing compensation for phase 1, the researcher described 
phase 2 to the participant (please see Appendix E “Information Sheet #2”). She was told that the 
second phase involved unsupervised collection of a urine sample and that she would be 
compensated with a second $20 gift card. If the woman agreed to participate, the researcher took 
the participant to the public restroom located in the adjacent hallway, informed her that a urine 
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cup was located in the metal cabinet behind the door and instructed her to place the cup back in 
the cabinet once she provided the sample. After the participant left the restroom, the researcher 
gave her another $20 gift card and an information sheet (see Appendix F “Information Sheet 
#3”) that debriefed her on why Phase 1 and 2 were conducted separately and thanked her for 
participating. Once she left, the staff member entered the research office adjacent to the 
bathroom, retrieved the urine sample from the cabinet and assayed the sample for drugs using the 
test cup.  Test results were recorded, along with the participant’s identification number, and then 
the test strip was wrapped in paper towel and disposed of in a waste basket.  
Data Analysis Plan 
In order to maintain consistency with procedures used to develop the original WIDUS 
and to allow for comparison, the present study used data analytic procedures similar to those 
employed in Dr. Ondersma’s R21 NIDA grant.  Specifically, this included randomly dividing the 
sample into a training sample (n = 131) and a validation sample (n = 100) in order to develop and 
validate indirect measures. In addition, a similar multi-step strategy (described below) was used 
to reduce the initial item pool and evaluate the predictive validity of these indirect measures. 
Research question 1. The first research question asked whether women in this sample 
minimized or denied prenatal drug use and if so, to what extent did self-report differ from UDS 
results. Hypothesis 1 predicted that rates of drug use by urinalysis drug assay would be greater 
than rates by self-report. To test this hypothesis, rates of self-reported past month drug use and 
positive drug status were compared.  
Research question 2. The second research question asked whether pregnancy variables 
contributed additional predictive validity to the WIDUS. Forty-five pregnancy items were 
evaluated. The item, “how many weeks pregnant are you” was used as demographic data. To 
address this question, we reduced the number of variables predictive of positive drug status using 
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a three-step process with the training sample (n=131). This process included removing items 
based on:  
1) Exclusionary criteria. Frequencies of positive endorsement and Flesch-Kincaid 
ratings of reading grade level were determined for each item. Items were removed 
based on poor endorsement (i.e., endorsement less than 10%) and high reading levels 
(i.e., Flesch-Kincaid rating higher than a 9th grade reading level). 
2) Univariate relationship with drug status. Each remaining variable’s univariate 
association with urine toxicology results was then examined by performing a chi-
square test for independence. A total of 13 variables (12 items with the largest chi-
square value plus the plus the total score for the original WIDUS) were chosen for 
inclusion in the next step based on the recommended 10:1 events per variable ratio in 
logistic regression analysis (Peduzzi, Concato, Kemper, Holfond, & Feinstein, 1996) 
and given the training sample size of 131. 
3) Multivariate relationship with drug status. In this step, hierarchical logistical 
regression was used to examine the multivariate relationship between these 12 
variables and drug status, above and beyond the WIDUS. Participants’ drug status 
was entered as the criterion variable, the WIDUS was entered at block 1 and the 12 
pregnancy variables were entered at block 2. Subsequent hierarchical logistical 
regressions were performed to determine the final item(s) to be included. 
Following this process, ROC curve analyses were conducted to determine the predictive validity 
of adding the pregnancy item(s) identified in step three to the WIDUS. A ROC curve plots the 
rate of true positives (sensitivity) against the false positive rate (1- specificity) for different 
possible cutoff scores of a test. The more closely the curve follows the left-hand and top borders, 
the more accurate the measure. Area under the curve (AUC) is the likelihood that any given 
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positive case will score higher than a given negative case on the screening tool and is commonly 
used as a summary measure of classification accuracy. An AUC of .50 signifies that the 
screening tool is accurately classifying positive cases at a rate equivalent to chance (Swets, 
1988). Sensitivity (the percentage of women with a positive urine screen who are also identified 
as at-risk by the screener) and specificity (the percentage of women with a negative urine screen 
who are also identified as not at-risk by the screener) for this new measure were calculated. 
Given the primary goal of this measure was to identify women who used drugs during 
pregnancy, sensitivity was valued over specificity in determining a cut-off score. Sensitivity was 
also prioritized because of the small consequences of false positives; it is be more desirable for a 
non-drug using woman to screen positive and receive intervention than for a drug-using woman 
to screen negatively and miss intervention. Positive predictive value (i.e., the percentage of 
women who are positive on the screener who also have a positive toxicology screen), negative 
predictive value (i.e., the percentage of women who are negative on the screener who also have a 
negative toxicology screen) and percent correctly classified were also calculated for the measure 
at the optimal cut-off score. 
Cross-validation. The addition of the pregnancy item(s) to the WIDUS was cross-
validated in the validation sample (n=100) using hierarchical logistic regression, ROC curve 
analysis, and other statistics (positive predictive value, negative predictive value, and 
classification accuracy).  
Research question 3. The third research question asked which indirect items, including 
both general and pregnancy variables, best predicted recent drug use. Three demographic items 
(i.e., age, ethnic background and EGA) were not included, reducing the total number of indirect 
items evaluated to 83. To determine which items should be included in the pregnancy screener 
(i.e., the Wayne Indirect Drug Use Screener- Pregnancy; WIDUS-P), the same three-step 
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procedure used in question 2 was applied to data from the training sample and used to reduce the 
number of items to a 4-7 item measure. This process included removing items based on:  
1) Exclusionary criteria. Frequencies of positive endorsement and Flesch-Kincaid 
ratings of reading grade level were calculated for each item. Items were removed 
based on poor endorsement (i.e., endorsement less than 10%), high reading levels 
(i.e., Flesch-Kincaid rating higher than a 9th grade reading level), highly stigmatizing 
content (e.g., abuse, violence, involvement with police) and direct alcohol and illicit 
drug content (e.g., family history of drug or alcohol problems, marijuana use by 
friends or partner). 
2) Univariate relationship with drug status. Chi-square tests of independence were 
calculated for all remaining variables to evaluate their univariate association with 
urine toxicology results. Thirteen variables were chosen for inclusion in the next step 
based on previously mentioned N:k ratio recommendation. 
3) Multivariate relationship with drug status. In Step 3, we performed a series of 
logistic regression analyses to assess each of the 13 variables’ multivariate 
association with drug status in order to further reduce the item count. In the first 
logistic regression, items with a p-value greater than .5 were eliminated. Additional 
logistic regression analyses were performed to remove items with lower odds ratios 
and higher levels of significance. The primary consideration in retaining items was 
the size of their association with drug status, rather than significance. The remaining 
items were combined to form the WIDUS-P. 
ROC curve analysis was conducted to determine the predictive validity of the WIDUS-P and an 
optimal cut-off score. PPV, NPV and percent correctly classified were also calculated for the 
determined cut-off score. 
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Cross validation. The WIDUS-P was then cross-validated on the validation sample (n= 
100) using logistic regression and ROC curve analyses. Other statistics of predictive validity 
(PVV, NPV and classification accuracy) were also calculated. To supplement these cross-
validation analyses, we selected five random samples of 100 participants (among the total 
sample, N=231) and calculated AUC, sensitivity, specificity, PPV, NPV and classification 
accuracy to further examine the validity of the WIDUS-P.  
Finally, we performed two hierarchical logistic regression analyses in order to compare 
the WIDUS-P to the WIDUS. For both analyses, participants’ drug status was entered as the 
criterion variable. For the first analysis, the WIDUS was entered at block 1 and the WIDUS-P 
was entered at block 2. The reverse was entered for the second logistic regression analysis. 
Research question 4. Given the frequent use of direct screening tools to identify at-risk 
drug use, the fourth research question examined the predictive validity of these methods 
compared to that of indirect methods (i.e., the WIDUS, WIDUS-P and the additional indirect 
measure adapted in questions two). The second hypothesis predicted that indirect screening tools 
would be a better predictor of recent drug use than direct screening methods. To evaluate this 
hypothesis, sensitivity for each direct screening method (i.e., the DAST, Drug CAGE, and single 
questions of lifetime, pre-pregnancy and past month drug use) was calculated and compared to 
the sensitivity of indirect methods. Specificity, PPV, NPV and classification accuracy were also 
determined for all methods to provide additional comparison. 
Results 
Recruitment 
 Study recruitment took place between May 28, 2010 and May 31, 2011.  While it is likely 
that women were screened eligible on multiple occasions (due to attending multiple OB visits 
during the recruitment period) and thus this number is likely an overestimation, 1571 women 
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were eligible for study participation.  Of these women, N=245 (16%) pregnant women provided 
informed consent and completed Phase 1 (computerized assessment).   Of these, N=231 (94%) 
also completed Phase 2 (provided urine sample for drug assay).   For the n=14 women who 
began phase 1, reasons given for not continuing study participation included: not having enough 
time (n = 6), not being able to urinate (n = 4) and being too tired (n = 1). An additional three 
women did not provide an explanation for their decision. One woman provided consent but did 
not provide any data, thus only 13 women completed phase 1. Descriptive data from these non-
completers (i.e., completed phase 1 only) are presented in Table 4 as a comparison to data from 
participants who completed both phases of the study (i.e., participants who also provided a urine 
sample).  None of the non-completers self-reported recent (i.e., past month) drug use, compared 
to 5% of study completers (11 of 231 women). 
Recoding of Variables 
Several variables were re-coded or computed prior to data analysis to adjust for their 
association with drug status. A value of “1” was assigned to the response consistent with the 
variable’s predicted direction of association with drug use. For the item concerning pregnancy 
intention, responses of “I wanted to be pregnant later,” “I didn’t want to be pregnant then or at 
any time in the future,” and “I don’t know” (i.e., unintended pregnancy) were coded as “1” and 
responses of “I wanted to be pregnant sooner” and “I wanted to be pregnant then” (i.e., intended 
pregnancy) were coded as “0”.  Relationship status was re-coded so that “I am not in a 
relationship” signified “1.”  Although the item regarding amount of contact with the father of the 
baby was originally categorical, with three response options, one response (“I don’t know the 
father of this baby that well”) was never endorsed.  Instead, the variable was re-coded into 
current contact (coded “0”) and past contact only (coded “1”). In addition, continuous variables 
concerning prenatal characteristics were dichotomized according to cut-offs identified by quartile 
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frequencies and the variable’s hypothesized relationship with drug status. For instance, the item, 
“how many weeks pregnant were you when you first thought you might be pregnant,” was coded 
positive if the participant responded 4 or more weeks (82% of the sample). The items concerning 
number of weeks pregnant at first OB appointment (6 weeks or more coded as “1”; 83% of 
sample endorsed this response) and number of pregnancies (multigravida coded as “1”; 71% of 
the sample endorsed this response) were also dichotomized. Finally, several variables were 
reverse-coded to account for their direction of association with drug status. For example, being 
unmarried has been shown to be significantly associated with prenatal drug use (El Marroun et 
al., 2008) so the item, “I am currently married,” was reverse-scored. Other recoded items were “I 
graduated from high school or completed my GED,” “I am currently working 20 hours or more 
per week,” “I currently have health insurance through an employer,” “I almost always use 
condoms during sex,” and “I am currently in a relationship.”  
Item Endorsement 
 Rates of positive endorsement for indirect items ranged from 2% to 72%. Table 3 
presents the rate of positive endorsement for each dichotomous item in the full sample (N = 231) 
in order from most to least commonly endorsed. Frequencies for the reverse-coded items 
(symbolized with an asterisk in Table 4), rather than for the original item, are presented in this 
table (e.g., 65% of participants do not currently have health insurance through an employer). 
Categorical and continuous pregnancy variables were previously described in Tables 2 and 3, 
respectively.  
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Table 4 
 
WIDUS-P Item Responses  
# Type Item % Yes 
   N= 231 n =13a 
11 G I often eat fast food and/or junk food 72 70 
7 P I currently receive some form of public assistance, such as food 
stamps, WIC, Medicaid, SSI or TANF 
70 62 
6 G *I currently have health insurance through an employer, either 
mine or a family member’s 
65 62 
10 P *I almost always use condoms during sex 65 62 
5 G *I am currently working less than 20 hrs per week 64 54 
12 G I have been treated at an emergency room in the past year 63 54 
54 G I get bored easily 63 54 
21 G Most of my friends think marijuana is no big deal 62 54 
58 G At least one person in my immediate family (parent, brother, or 
sister) has had problems with depression 
59 62 
22 P I have at least one caffeinate beverage (for example, caffeinated 
soda, coffee, or energy drink) every day 
58 69 
34 G There have been times in my life, for at least two weeks straight, 
where it felt like everything was an effort 
57 69 
61 G I am easily upset about things 52 23 
8 P At least once in my life, I have been diagnosed with a STD, such as 
gonorrhea, Chlamydia, Herpes, syphilis, HIV, or any other STI 
51 70 
19 G Most of my friends smoke cigarettes 49 46 
33 P There have been times in my life, for at least two weeks straight, 
where I felt so down or depressed that nothing could cheer me up 
49 39 
46 P It’s hard to get places because of transportation 48 39 
47 P In the past 12 months, I’ve worried about my housing situation 48 15 
64 P Over the past month, I have felt down, depressed, or helpless 48 23 
16 G I was a daily smoker during the year before I learned I was 
pregnant 
47 39 
20 G At least two of my closest friends use marijuana 47 39 
37 P One or more of my biological parents have had a problem with 
drugs or alcohol 
47 54 
41 P In my lifetime, I have been hit, slapped, kicked or otherwise 
physically hurt by someone 
47 23 
85 P The father of this baby currently smokes cigarettes 47 39 
15 G I have smoked at least 100 cigarettes in my entire life 46 46 
18 G I’m often around second hand cigarette smoke 46 31 
32 G There have been times in my life, for at least two weeks straight, 
where I felt completely hopeless about things 
45 46 
14 G In the past year, I have been bothered by pain in my teeth or mouth 44 31 
51 G I get mad easily and feel a need to blow off some steam 44 23 
17 G I smoked at least one cigarette the week before I learned I was 
pregnant 
43 46 
65 G Drugs are everywhere in my neighborhood 43 31 
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31 G There have been times in my life, for at least two weeks straight, 
where I felt completely worthless 
39 31 
53 G I feel overwhelmed by my life and my problems 38 15 
57 G I experience “flashbacks” of bad things that have happened to me 38 31 
86 P The father of this baby thinks marijuana is no big deal 36 39 
36 G As an adult, I have seen somebody get stabbed, shot, or seriously 
beaten 
35 23 
66 G I often have trouble sleeping (not counting during pregnancy) 34 31 
67 P I feel very overwhelmed when thinking about taking care of a new 
baby 
34 31 
68 P I have repeated and disturbing memories of a stressful thing that 
happened to me 
33 31 
69 G I lose my temper very easily 33 23 
63 G I have seen or experienced worse things than most other people 
have 
31 15 
24 P When I was a child, I saw someone get stabbed, shot, or seriously 
beaten 
30 15 
23 P When I was a child, I saw adults in my home physically hurting 
each other 
28 23 
42 P There have been times in my life I have not felt safe around my 
current partner or past partner 
28 8 
50 G Things have usually gone against me in life 28 8 
38 G One or more of my brothers or sisters has had a problem with 
drugs or alcohol 
27 31 
60 G In elementary school, I often got into trouble with teachers or the 
principal because of my behavior (fighting, talking in class, or 
coming to class late) 
27 8 
39 G I have been abandoned by someone I love more than most people 
have 
26 15 
3 G *I am currently married 25 8 
25 P When I was a child, an adult hit me hard enough to cause bleeding, 
bruises, or welts 
25 8 
40 G I have been in trouble with the police 25 8 
26 P When I was a child, an adult touched my private parts in a sexual 
manner, or got me to touch their private parts in a sexual manner 
24 8 
48 P I often move from place to place 23 0 
80 P Have you ever had a pregnancy that ended during the first 4 
months (not including an abortion)? 
23 15 
4 G *I graduated from high school or completed my GED 22 15 
13 G I have missing teeth 22 23 
45 P In the past year, I’ve gone hungry because I didn’t have enough 
money to buy food 
22 0 
82 P Have you ever had an abortion? 22 23 
30 P Since my sixteenth birthday, I have been injured in an assault or 
fight (not counting during sports) 
21 15 
71 G I often feel empty inside 21 0 
49 P In the past year, the police have been called to my home because of 20 0 
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a fight or argument 
27 P When I was a child, I saw people using drugs in my home 19 8 
43 P Within the last year, I have been hit, slapped, kicked or otherwise 
physically hurt by someone 
19 8 
52 P Some of my immediate family members are pretty violent 17 0 
72 P In the past, I have attempted to hurt myself 17 23 
70 P In the past, I have told someone I was going to hurt myself 16 31 
55 G I live life on the edge 14 8 
28 P Since my sixteenth birthday,  I have had fractures or dislocations to 
my bones or joints 
12 8 
35 G As an adult, I have been badly beaten up at least once 12 8 
62 G When I was younger than 13 years old, I often stayed out past 
midnight 
11 0 
56 P I have conflict with people in authority, like teachers, supervisors, 
and the police 
10 0 
44 P During my current pregnancy, I have been hit, slapped, kicked or 
otherwise physically hurt by someone 
8 8 
81 P Have you ever had a pregnancy that ended after 4 months but 
before birth? 
8 8 
79 P Have you ever had a baby that died during birth or was stillborn? 7 8 
84 P Current contact with father of this baby 7 0 
59 P I sometimes do really harmful things to myself 5 0 
29 P Since my sixteenth birthday, I have injured my head 4 0 
9 P I have been diagnosed with Hepatitis C 2 0 
Note. * = Item was changed from original item to reflect reverse-coding; G = general item. P = pregnancy item. Item 
responses were true/false or yes/no. 
a13 women consented for study participation but did not complete phase 2. 
 
Prenatal Drug Use 
Prevalence of drug use. Rates of drug use varied by type of report (i.e., self-report 
versus urine drug screening) and time frame. Urinalysis documented higher rates of recent drug 
use than self-report.  Forty-three participants (19%) tested positive for at least one drug.  When 
drugs that could have been consumed with a prescription (i.e., benzodiazepines, methadone, 
opiates and oxycodone) were excluded from analyses, the rate decreased to 16% (n = 36). Note, 
this prevalence rate and not the abovementioned rate is used to describe recent drug use by UDS 
for the remainder of the study. Among self-reported drug use, prevalence of lifetime drug use 
was the highest (39%, n = 90), followed by use during the 3 months prior to pregnancy (20%, n 
= 46) and lastly, past month drug use (5%, n = 11). Interestingly, in response to question #1 on 
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the DAST, only 19% (n = 43) of participants reported using drugs “other than those required for 
medical reasons” in the past 12 months. This difference highlights the inconsistency in self-
reported drug use: 20% reported using in the three months prior to pregnancy, but only 19% 
reported using in the past year. 
Type of drug use. The most commonly used drug, according to urinalysis, was 
marijuana. Among the total sample, 15% (n = 34) of participants tested positive for marijuana. A 
much smaller percentage tested positive for methadone (1.7%, n = 4), opiates (1.7%, n = 4), 
oxycodone (1.3%, n = 3), cocaine (0.9%, n = 2), methamphetamines (0.4%; n = 1), and 
barbiturates (0.4%, n = 1). Benzodiazepines, MDMA, and PCP were not recently used by 
pregnant women in this sample. Table 5 describes the type of drug use by participants coded as 
“drug positive.” Most drug-using women tested positive for marijuana only (89%). 
Table 5 
 
Type of Drug Use among “Drug Positive” Participants, n = 36  
Type n 
Marijuana  32 
Marijuana and cocaine  1 
Marijuana and methamphetamine  1 
Cocaine  1 
Barbiturates 1 
 
Research question 1: Self-reported drug use versus UDS.  
In support of Hypothesis 1, the rate of drug use by urinalysis (16%, n = 36) was three 
times higher than the rate by self-report (5%, n =11). Two-thirds of the women who tested 
positive (67%, n = 15) denied using in the past month. 
Research Question 2: Predictive Validity of Pregnancy Variables 
Step 1: Exclusionary criteria. Fifteen items were removed for under endorsement (i.e., 
< 10%) and high reading levels (i.e., if they required a 9th grade reading level or higher according 
to Flesch-Kincaid ratings), reducing the item count to 30. In addition, the item, “How many of 
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these pregnancies ended in the birth of a live baby” was removed because it was dependent on a 
previous item and could be not evaluated independently.  
Step 2: Univariate relationship with drug status. The twelve items with the largest chi-
square value were retained (values ranged from 2.93 to 10.27).  
Step 3: Multivariate relationship with drug status. Of the 12 variables entered into the 
hierarchical logistic regression in block 2 (block 1 = WIDUS), three items with the lowest p-
value (p < .35) and highest odds ratio (Exp(B) > 2) were retained: abortion (Exp(B) = 3.38, p = 
.046 ), assistance (Exp(B) = 2.939, p = .23) and housing (Exp(B) = 2.08, p = .31). Hierarchical 
logistic regression was repeated with only the abortion, assistance and housing items entered at 
block 2. Table 6 presents the odds ratios and significance of each predictor in this model and 
shows that the abortion variable was the only one to retain significance. The addition of these 
variables at block 2 was statistically significant, χ2(3) = 10.61, p = .014, and increased the rate of 
correction classification from 77% to 83%.  
Table 6 
 
Summary of Hierarchical Logistic Regression Analysis for WIDUS + Pregnancy Variables Block 
2 (N = 131) 
Variable Sig. OR 95% CI 
WIDUS .02 1.55 [1.06, 2.28] 
Abortion .02 3.40 [1.17, 9.84] 
Housing .14 2.44 [.75, 7.99] 
Assistance .17 3.11 [.62, 15.67] 
Note. Sig. = p-value; OR = odds ratio; CI = confidence interval; Abortion = Have you ever had an abortion; 
Assistance =  I currently receive some form of public assistance, such as food stamps, WIC, Medicaid, SSI, or 
TANF; Housing = In the past 12 months, I’ve worried about my housing situation. 
 
Next, we examined the addition of the abortion item to the WIDUS. In a hierarchical 
logistic regression analysis, the WIDUS was entered at block 1 and the abortion item was entered 
at block 2. Odds ratios for the WIDUS and abortion item are reported in Table 7. The abortion 
item added significant additional variance to the WIDUS, χ2(3) = 6.06, p = .01. The effect size of 
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adding abortion to the WIDUS was small, with Cox and Snell R-square = .15 and Nagelkerke R-
square = .24.  
Table 7 
 
Summary of Hierarchical Logistic Regression Analysis for WIDUS + Abortion Block 2 (N = 
131) 
Variable Sig. OR 95% CI 
WIDUS <.001 1.91 [1.35, 2.69] 
Abortion .014 3.75 [1.31, 10.71] 
Note. Sig. = p-value; OR = odds ratio; CI = confidence interval; Abortion = Have you ever had an abortion. 
 
The ROC curve for the WIDUS+abortion showed an AUC of .77 (standard error = .045, 
p < .001, 95% CI = .68, .85), indicating that there is a 77% likelihood that a randomly selected 
woman with a positive UDS will have a higher WIDUS+abortion score than a randomly selected 
woman with a negative UDS. This is a slight improvement in classification accuracy from the 
WIDUS (AUC = .74, standard error = .05, p < .001, 95% CI = .65, .84). ROC curve analysis 
indicated that a cut-off score of 4 optimized sensitivity (.81). Specificity was .57. At this cutoff 
score, the measure’s positive predictive value (i.e., the percentage of women who are positive on 
the WIDUS+abortion who also have a positive toxicology screen) was .32 and negative 
predictive value (i.e., the percentage of women who are negative on the WIDUS+abortion who 
also have a negative toxicology screen) was .92. Overall, the WIDUS+abortion, with a cutoff 
score of 4, correctly classified 71% of cases. 
Cross-validation. When the hierarchical logistic regression (block 1 = WIDUS, block 2 = 
abortion) was repeated, the abortion item did not significantly predict drug status above and 
beyond the WIDUS, χ2(1) = 2.22, p = .14; however the effect of the variable still maintained its 
magnitude (OR = 3.0, p = .13, 95% CI = .724, 12.41). Using a cut-off score of four, sensitivity 
was high (.80) with moderate specificity (.66). The positive predictive value was .21, while the 
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negative predictive value was .97. Overall, the WIDUS plus the abortion item correctly classified 
76% of participants. 
Research Question 3: Predictive Validity of Indirect Items within a Pregnant Sample 
Step 1: Exclusionary criteria. Nineteen items were removed for under endorsement (i.e., 
< 10%), high reading levels (i.e., Flesch-Kincaid 9th grade reading level rating or higher), highly 
stigmatizing content (e.g., abuse, violence, involvement with police) and direct alcohol and illicit 
drug content (e.g., family history of drug or alcohol problems, marijuana use by friends or 
partner) were eliminated. This step removed 19 items, reducing the item count to 64. 
Step 2: Univariate relationship with drug status. The 13 items with the largest chi-
square value were retained (values ranged from 4.82 to 15.99) and included in step three.  
Step 3: Multivariate relationship with drug status. In the first logistic regression, items 
with a p-value greater than .5 were eliminated, removing five of the 13 items. Table 8 shows the 
subsequent two logistic regression analyses. In the eight predictor model, the upset and friends 
cigarettes items were removed because of their lower odds ratio and higher level of significance 
in comparison to the other six items. This resulted in the six predictor model. As seen in Table 8, 
these six items were strongly associated with drug status (odds ratios range from 2.82 to 16.85) 
and therefore were retained. As previously mentioned, the primary consideration for retaining 
these items was the size of their association with drug status, rather than significance.  
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Table 8 
 
Summary of Logistic Regression Analyses in the Training Sample 
Variable Sig.        OR 95% CI 
Eight Predictorsa 
Midnight .002 15.58 [2.65, 91.68] 
Abortion .008 6.18 [1.61, 23.77] 
100 cigarettes .012 6.86 [1.53, 30.80] 
Pain .015 5.34 [1.39, 20.52] 
Seen worse .086 2.74 [.87, 8.69] 
Hours .139 2.98 [.70, 12.67] 
Upset .270 2.08 [.57, 7.59] 
Friends cigarettes .691 0.76 [.19, 2.98] 
Six Predictorsb 
Midnight .001 16.85 [3.06, 92.76] 
Abortion .011 5.45 [1.47, 20.13] 
100 cigarettes .008 6.37 [1.61, 25.19] 
Pain .016 5.06 [1.36, 18.87] 
Seen worse .079 2.82 [.89, 8.96] 
Hours .120 3.03 [.75, 12.22] 
Note. Sig. = p-value; OR = odds ratio; CI = confidence interval; 100 cigarettes = I have smoked at least 100 
cigarettes in my entire lifetime; Abortion = Have you ever had an abortion; Friends cigarettes = Most of my friends 
smoke cigarettes; Hours = I currently work less than 20 hours per week; Midnight = When I was younger than 13 
years old, I often stayed out past midnight; Pain = In the past year, I have been bothered by pain in my teeth or 
mouth; Seen worse = I have seen or experienced worse things than most other people have; Upset = I am easily 
upset about things.  
aLogistic regression model with eight predictors. 
bLogistic regression model with six predictors. 
 
The six indirect items listed in Table 8 were combined to form the WIDUS-Pregnancy 
(WIDUS-P). The ROC curve for the WIDUS-P is presented in Figure 1 and shows an AUC of 
.87 (standard error = .036, p < .001, 95% CI = .80, .94), indicating that there is an 87% 
likelihood that a randomly selected woman with a positive UDS will have a higher WIDUS-P 
score than a randomly selected woman with a negative UDS. Said another way, the WIDUS-P 
demonstrated good accuracy in classifying women who tested positive for recent drug use.  
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Figure 1. ROC curve for the six-item WIDUS-P measure predicting prenatal drug use in the 
training sample. Diagonal line represents chance prediction. AUC = .87. 
 
Table 9 lists the sensitivity and specificity for each possible cut-off score and also 
displays the dramatic changes in sensitivity and specificity associated with a change in cut-off 
score. Given the primary consideration of sensitivity, the optimal cut-off score was three 
(sensitivity = .89). At this cutoff score, the measure’s positive predictive value (i.e., the 
percentage of women who are positive on the WIDUS-P who also have a positive toxicology 
screen) was .40 and negative predictive value (i.e., the percentage of women who are negative on 
the WIDUS-P who also have a negative toxicology screen) was .96. Overall, the WIDUS-P, with 
a cutoff score of 3, correctly classified 70.8% of cases. 
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Table 9 
 
WIDUS-P Cutoff Score Sensitivity and Specificity N= 131 
WIDUS-P score 
positive if greater 
than or equal to: 
Sensitivity Specificity % Positive 
1 1.00 .14 89 
2 1.00 .39 68 
3 .89 .66 45 
4 .62 .91 19 
5 .19 .99 4.6 
6 .08 1.00 1.5 
Note. WIDUS-P score = sum of 6 items rated from 0 to 1. 
 
Cross-validation procedures and analyses. The 6-item WIDUS-P was then cross-
validated on the validation sample (N = 100).  Scores on the WIDUS-P were reasonably well-
distributed (mean = 2.28, SD = 1.39, skewness = .21, kurtosis = -.41) and yielded an AUC of .85 
(standard error = .05, p < .001; see Figure 2), only a slight decrease from an AUC of .87 in the 
training sample. The 95% confidence interval for the AUC was .76 to .94. Although scores on 
the WIDUS-P were generally well-distributed, positive cases were more common with higher 
scores (with the exception of a score of 6; see Table 10), resulting in an irregularly shaped curve. 
As shown in Table 11, there was an improvement in sensitivity and specificity for a cut-off score 
of 3 in the validation sample (.90 and .74, respectively). Similar to the ROC curve for the 
training sample, the ROC curve for the validation sample showed dramatic changes in sensitivity 
and specificity associated with changes in cut-off score steps. The positive predictive value of 
the WIDUS-P decreased to .28, which meant that 28% of participants who had a positive 
WIDUS-P score tested positive for drug use. The negative predictive value was .99. 
Classification accuracy improved from 70.8% in the training sample to 76% in the validation 
sample.  
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Figure 2. ROC curve for the six-item WIDUS-P measure predicting prenatal drug use in the 
validation sample. Diagonal line represents chance prediction. AUC = .85. 
 
Table 10 
 
Percent of Drug Positive Participants as a Function of WIDUS-P score 
WIDUS-P score  % testing positive N 
0 0% 13 
1 0% 25 
2 3.3% 30 
3 27% 15 
4 30% 10 
5 29% 7 
6 - 0 
Note. n = 100. 
 
Table 11 
 
WIDUS Cutoff Score Sensitivity and Specificity n = 100 
WIDUS-P score 
positive if greater 
than or equal to: 
Sensitivity Specificity 
1 1.00 .14 
2 1.00 .42 
3 .90 .74 
4 .50 .87 
5 .20 .94 
6 .00 1.00 
Note. WIDUS-P score = sum of 6 items rated from 0 to 1. 
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 A logistic regression was performed to determine how strongly the six items that 
comprised the WIDUS-P predicted drug status. Results are shown in Table 12. All items, with 
the exception of the hours item, performed in the predicted direction (i.e., increased the odds of 
testing positive for recent prenatal drug use). 
Table 12 
 
Summary of Logistic Regression Analyses in the Validation Sample 
Variable Sig.        OR 95% CI 
Midnight .09 5.43 [0.79, 37.52] 
Abortion .02 10.37 [1.50, 71.83] 
100 cigarettes .26 2.67 [0.49, 14.58] 
Pain .23 0.32 [0.05, 2.02] 
Seen worse .02 11.05 [1.56, 78.52] 
Hours .71 1.50 [0.18, 12.11] 
Note. Sig. = p-value; OR = odds ratio; CI = confidence interval; 100 cigarettes = I have smoked at least 100 
cigarettes in my entire lifetime; Abortion = Have you ever had an abortion; Friends cigarettes = Most of my friends 
smoke cigarettes; Hours = I currently work less than 20 hours per week; Midnight = When I was younger than 13 
years old, I often stayed out past midnight; Pain = In the past year, I have been bothered by pain in my teeth or 
mouth; Seen worse = I have seen or experienced worse things than most other people have; Upset = I am easily 
upset about things.  
 
Additional cross-validation procedures. Table 13 presents data from ROC curve 
analyses of five random samples (from the full sample) of 100 participants: the WIDUS-P (cut-
off score = 3), on average, maintained good classification accuracy (AUC = .86), sensitivity (.88) 
and specificity (.69). 
Table 13 
 
Cross-validation of the WIDUS-P (cutoff score = 3) in Five Randomly Selected Samples  
Sample AUC (SE)* Sensitivity Specificity PPV NPV Classification 
Accuracy 
1 .88 (.04) .95 .64 .38 .98 70% 
2 .90 (.04) .94 .74 .41 .98 77% 
3 .84 (.05) .87 .67 .32 .97 70% 
4 .89 (.04) .93 .73 .38 .98 76% 
5 .79 (.06) .73 .66 .28 .93 67% 
Average .86 .88 .69 .35 .97 72% 
Note. N = 100; AUC = area under the curve; SE = standard error. 
* p < .001. 
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 WIDUS-P versus WIDUS. Table 14 describes the results of a hierarchical logistic 
regression examining the effect of WIDUS-P on drug status, after controlling for the WIDUS. As 
shown, the WIDUS-P was a significant predictor of drug status after controlling for the effect of 
the WIDUS (χ2(1) = 6.05, p < .05). Table 15 shows the reverse: the effect of WIDUS on drug 
status after controlling for the WIDUS-P. Unlike the results of previous analysis, the WIDUS 
was not a significant predictor of drug status above and beyond the WIDUS-P (χ2(1) = .003, p > 
.05). Although both measures were significant predictors of drug status when compared alone to 
the constant-only model (as shown in Block 1 of Table 14 and 15), only the WIDUS-P offered 
significant additional predictive validity.  
 
Table 14 
 
Effect of the WIDUS-P on Drug Status, Controlling for the WIDUS 
Variable Sig.        OR 95% CI 
Block 1a 
WIDUS .01 1.82 [1.13, 2.93] 
Block 2b 
WIDUS .96 1.02 [.52, 2.00] 
WIDUS-P .02 2.54 [1.16, 5.14] 
Note. N = 100. Sig. = p-value; OR = odds ratio; CI = confidence interval. 
aχ2(1) = 7.30, p < .01. 
bχ2(1) = 6.05, p < .05. 
 
Table 15 
 
Effect of the WIDUS on Drug Status, Controlling for the WIDUS-P 
Variable Sig.        OR 95% CI 
Block 1a 
WIDUS-P .001 2.48 [1.44, 4.28] 
Block 2b 
WIDUS-P .02 2.45 [1.16, 5.14] 
WIDUS .96 1.02 [.52, 2.00] 
Note. N = 100. Sig. = p-value; OR = odds ratio; CI = confidence interval. 
aχ2(1) = 13.35, p < .001. 
bχ2(1) = .003, p > .05. 
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Research Question 4: Direct versus Indirect Measures of Prenatal Drug Use 
Sensitivity, specificity, PPV, NPV and classification accuracy for the standardized 
measures, the DAST and Drug CAGE, single questions of lifetime, pre-pregnancy and past 
month drug use, and the indirect methods (WIDUS, WIDUS+abortion, WIDUS-P) are presented 
in Table X. As predicted in Hypothesis 2, the indirect measures outperformed all direct measures 
of prenatal drug use with regard to sensitivity. The WIDUS and the WIDUS-P identified almost 
90% of all drug users; however, the WIDUS-P was a more specific measure. The 
WIDUS+abortion was less sensitive, but still identified more drug-users than direct methods. 
Among the direct methods, the DAST, with a cutoff score of one, identified the highest 
percentage of prenatal drug users (72%) and also demonstrated good specificity (.76). Using a 
higher cutoff score for both the DAST and Drug CAGE resulted in higher specificity, but it 
reduced sensitivity by almost half. Sensitivity of the direct questions increased as the time period 
in question became more remote; the inverse relationship was observed for specificity. Asking 
participants if they used drugs in the past month correctly identified the greatest number of 
participants (91%); however, this question only identified 34% of drug users.  
In addition, Table 16 reports the percentage of participants who screened positive on a 
measure (based on the cut-off score reported in parentheses) or positively endorsed a question. 
Based on comparison of self-reported last month drug use to the DAST and Drug CAGE scores, 
women appear more willing to disclose drug use consequences (32% for both measures) than 
admit to recent drug use (5%). 
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Table 16 
 
Accuracy of indirect and direct screening tools in identifying prenatal drug use, N = 231 
Screening Method Sensitivity Specificity PPV NPV Classification 
Accuracy 
% Positive
WIDUS-P (3)a .90 .74 .28 .99 76.% 32 
WIDUS (3)  .89 .44 .23 .96 51% 61 
WIDUS+abortion (4)a .80 .66 .21 .97 76% 39 
DAST (1) .72 .76 .36 .94 75% 32 
Lifetimeb .69 .66 .28 .92 67% 39 
CAGE (1) .64 .75 .32 .92 73% 32 
Three monthsc .58 .87 .46 .92 83% 20 
DAST (2) .39 .90 .42 .89 82% 14 
CAGE (2) .39 .87 .36 .88 79% 17 
Last monthd .34 .99 .91 .91 91% 5 
Note. Cutoff scores for the WIDUS, DAST, and CAGE are in parentheses. 
aStatistics are from the validation sample (N = 100). 
bDrug use endorsed in lifetime. 
cDrug use endorsed during the three months prior to pregnancy recognition. 
dDrug use endorsed in the last month. 
 
Discussion 
 The purpose of this study was to develop an indirect screening tool to detect prenatal 
drug use. The research built upon the work of Dr. Steven Ondersma and colleagues, during the 
development of the Wayne Indirect Drug Use Screener (WIDUS). The current study was an 
extension of this research, with a focus on detecting drug use in pregnant women. Four main 
research questions: (1) Are women in this population underreporting prenatal drug use?  If so, 
what is the extent of the discrepancy between self- and biological-report?, (2) Do pregnancy-
related variables offer additional predictive validity to an existing indirect drug screening tool 
developed with postpartum women (i.e., the WIDUS)?, (3) Considering both prenatal and 
general drug use correlates, what items best predict recent drug use in this sample of pregnant 
women?, and (4) How well do direct (e.g., standardized screening questions) and indirect 
measures of prenatal drug use predict objective evidence of such use (i.e., positive UDS)? It was 
hypothesized that women will underreport their prenatal drug use (Hypothesis 1) and that 
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indirect screening tools will better identify recent drug use than direct screening measures 
(Hypothesis 2). 
 The subsequent discussion will answer these questions by summarizing results of data 
analysis. The implications of these findings, as well as directions for future research, will then be 
presented.  Lastly, limitations of the study will be addressed.   
Research Question 1: Self-reported Drug Use versus UDS 
 When self-report and objective (USD) measures of prenatal drug use were compared, 
prevalence rates varied, evidencing underreporting in this study. As hypothesized, participants 
tested positive for recent drug use at a rate higher than they self-reported.This was true even after 
certain drugs that could have been used legally (i.e., with a prescription) were excluded, lowering 
the prevalence rate by biological report from 19% to 16%. Thus, even when using a conservative 
rate, only one-third of participants who tested positive self-reported drug use in the past month. It 
is likely that the “true” rate of prenatal drug use (i.e., use of any illicit drug during pregnancy) is 
even higher and would reflect higher rates of underreporting. Nonetheless, rates of 
underreporting are consistent with results from other urban, prenatal samples (Markovic et al., 
2000; Ostrea et al., 1992) and the the parent study (Grekin et al., 2010).  
Research Question 2: Predictive Validity of Pregnancy Variables 
The second research question- do pregnancy-related variables contribute additional 
predictive validity to the original WIDUS screener- was evaluated using N = 46 pregnancy-
related items. Surprisingly, only one item retained statistical significance at the end of the item 
reduction process. The abortion item added significant predictive validity above and beyond the 
WIDUS. While this item added significant predictive validity, above and beyond the WIDUS, 
the item focused on the controversial issue of abortion.  
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While it may be surprising that only the abortion item was significantly associated with 
prenatal drug status within the context of other risk factors, it is not unexpected that this item 
retained significance during multivariate analyses. Several studies have documented an 
association between abortion and mental health problems. However, there is discrepancy within 
the literature as to how this relationship is best conceptualized. Some researchers view abortion 
as a traumatic experience with negative psychological consequences (Coleman, Coyle, Shuping, 
& Rue, 2009), others attribute the association between abortion and mental health problems to 
common risk factors (i.e., SES, violence history, prior mental health, described in Steinberg & 
Finer, 2011). In an investigation of the common-risk-factors model with a nationally 
representative sample (i.e., women who responded to the abortion question as part of the 
National Comorbidity Survey Part II; N = 2065), Steinberg & Finer (2011) examined the 
relationship between history of abortion (0, 1, and multiple abortions) and having a substance use 
disorder (according to DSM III-R criteria). After controlling for socio-demographic (e.g., race, 
income, marital status) and other risk factors (e.g., intimate partner violence, age at first abortion 
or pregnancy), abortion (having multiple versus zero abortions) was significantly associated with 
having a current substance use disorder diagnosis (OR = 3.7, 95% CI = 1.2, 11.7). Although the 
strength of this association was reduced when common risk factors were controlled for (i.e., the 
OR decreased from 5.2, 95% CI = 2.2, 12.2), these findings still lend support to the current 
results concerning the predictive validity of the abortion item.  
Research Question 3: Predictive Validity of Indirect Items within a Pregnant Sample 
 Research question 3 concerns which indirect items, among both prenatal and general drug 
use correlates, best predict recent drug use. Utilizing the full item pool, six indirect items were 
retained during the item reduction process as a result of their univariate and multivariate 
relationships with drug status. Together, these six items formed the WIDUS-Pregnancy 
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(WIDUS-P). Two items, the 100 cigarettes and pain (in teeth or mouth) items, overlapped with 
the WIDUS. The abortion item, retained in question 2, was also included. Overall, the measure 
performed well in cross-validation analyses. The WIDUS-P showed good accuracy in 
distinguishing recent drug users from non-drug users (i.e., women with no evidence of recent 
prenatal drug use). Within the validation sample, it identified 90% of women who tested positive 
for recent drug use and almost three-quarters of women who did not test positive. With a cut-off 
score of three, the WIDUS-P correctly classified 76% of all women in the validation sample. In 
addition, it accounted for significant unique variance, not captured by the WIDUS, in predicting 
prenatal drug use. Data from randomly selected validation samples also support the classification 
accuracy and high sensitivity of this measure. 
Research Question 4: Direct versus Indirect Measures of Prenatal Drug Use 
Research question 4 focused on how well the direct self-report measures of drug use 
predicted prenatal drug use (i.e., positive UDS) in this sample of pregnant women. The indirect 
measures, the WIDUS, WIDUS+abortion and WIDUS-P, were superior to all direct measures 
and questions in terms of sensitivity. The WIDUS-P emerged as the most sensitive indirect 
measure as well as the most specific. The DAST and the Drug CAGE, using the lowest possible 
cut-off scores, were moderately sensitive screening tools; although, the DAST outperformed the 
CAGE (.72 versus .64). Overall, the direct methods (i.e., the question about last month use, the 
DAST with a cut-off score of 2, and the question about use during the 3 months prior to 
pregnancy recognition) accurately classified the most participants; however they had only poor 
to moderate sensitivity. For example, asking women if they used drugs in the past month 
correctly identified almost 91% of participants, but missed two-thirds of drug users. Given the 
study’s priority on identifying prenatal drug use, indirect measures were more successful at 
identifying UDS positive cases of prenatal drug use than direct methods. 
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Although, indirect methods clearly offer a predictive advantage, the utility of direct 
measures may be sample dependent. Results from Grekin and colleagues (2010), utilizing data 
from the parent study at Wayne State University, support a different perspective of the DAST’s 
sensitivity and disclosure of drug use. In their sample of 300 women who had recently delivered 
at an urban obstetric hospital in Detroit, the DAST was less accurate than in the current study in 
identifying prenatal drug use. For identifying any drug use (i.e., cocaine, amphetamines, opiates 
and/or marijuana), the DAST, with a cut-off of one, was less sensitive (.47 versus .72 in current 
study). Rates of self-reported past year drug use, according to the DAST-10, question #1, also 
differed between samples, with participants in the current sample endorsing higher rates (13% 
versus 19%).  
Overall, women in the present study self-reported drug use and its consequences more 
freely than women in the Detroit sample. Women in this study might have felt more comfortable 
disclosing for several reasons. One, they were in an outpatient setting versus a controlled 
environment, where they were only interacting with staff for a specified amount of time and 
could leave voluntarily. In addition, because women were still pregnant, the possible 
consequences of prenatal drug use (e.g., loss of custody) were less immediate and thus women 
might not have felt as vulnerable (Harris & Paltrow, 2003).  Lastly, some participants were 
recruited from “high-risk” clinics which included women with known medical conditions and 
substance problems that complicated pregnancy. For some participants, they may have felt more 
comfortable disclosing prenatal drug use because their medical providers were already aware of 
this information and/or they were openly seeking treatment for drug use. Together, differences 
between samples suggest that self-disclosure, and consequently, the utility of the DAST as a 
screening tool for prenatal drug use, may be sample dependent.  
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Implications and Future Directions   
 Implications of the present study’s results are discussed below within the context of 1) 
the sample’s severity of biopsychosocial risk factors, 2) advances in methodological issues 
related to screening for prenatal drug use and estimating rates of underreporting, and 3) indirect 
measures as a promising screening approach. Directions for future research are also described.  
Severity of psychosocial risk factors. While the primary focus of the present study was 
measure development, study findings also point out the nature and types of psychosocial risk 
factors that impact the target group of pregnant women.  Self-report data confirm that many 
witnessed or experienced various negative life events, including childhood physical and sexual 
abuse, physical abuse as an adult, and unsafe partner relationships. For many women, drugs were 
present in their childhood environments as well as during their current pregnancy.  About half 
the sample reported smoking cigarettes prior to becoming pregnant and a similar percentage 
reported that the father of their fetus was a current smoker.  Many women also had close friends 
who used marijuana. These data affirm the need for better screening and intervention programs 
focused not only on substance use but also other areas of risk.   
As a whole, current study participants were predominantly young, low-income, minority 
women and many noted this was not their first pregnancy. Health disparities research has found 
infant mortality and morbidity rate differences continue to be an area of much concern.  
Specifically, NCHS found the death rate for African American infants (13.3/1,000 live births) 
was two times higher than the national average of 5.6/1,000 live births (NCHS, 2011). Central to 
the problem of infant mortality is preterm birth (MacDorman, Callaghan, Mathews, Hoyert, & 
Kochanek, 2007), with African Americans accounting for the highest percentage of cases (17.8% 
versus 11.5% for Whites; Behrman & Stith-Butler, 2006). One important risk factor for such 
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outcomes is prenatal substance use.  Clearly, the present sample of women is at increased risk for 
having a preterm birth or other maternal or infant complications.  
It is important to recognize that the risks for adverse pregnancy-related outcomes are not 
limited to those women who screened positive for prenatal drug use by UDS or self-report. Many 
of the larger pool of women (84%) did not screen positive for prenatal drug use, but nonetheless 
remain at increased risk for poorer outcomes due to a variety of factors.  First, it is likely that 
some women were still missed with the more intensive screening procedures used in the present 
study. Urine drug assays have a limited window of detection (i.e., up to 2-3 weeks for regular 
marijuana use) and thus can only identify more recent use so the prevalence of any drug during 
pregnancy is likely to be higher.  Other women used pre-pregnancy but then stopped.  Many will 
return to use post-partum (Ebrahim & Gfroerer, 2003). A significant proportion of study 
participants reported current symptoms of depression or anxiety (about half reported “feeling 
down, depressed or hopeless,” and being “easily upset”).  Difficulty controlling anger was 
another common problem, with 52% of women noting they “get easily and [feel] a need to blow 
off some steam.” Current health and economic stressors (e.g., ER visits, poor nutrition, 
transportation issues, housing instability) were also quite common.  Collectively, this 
information suggests that in addition to interventions for prenatal drug use, there is a need for 
multi-faceted prevention and intervention efforts to promote general health and well-being in this 
at risk population of women and their children.  
Advances in methodological practices. During development and validation of an 
indirect drug use screener in the target population of low-income, minority women, several 
methodological considerations were given careful thought and consideration.   First, specific 
steps were taken to create an environment that assured patients of anonymity and confidentiality. 
For example, self-report surveys were administered using ACASI technology.  Such practices 
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tend to promote disclosure of sensitive behaviors (Durant et al., 2002; Newman et al., 2002). 
Second, the present project was one of the few that compared self-report screeners to a biological 
measure of drug use (i.e., urinalysis).  While urine drug screening is not without limitations, 
particularly for substances with a short half-life, it nonetheless provides a more objective 
measure of recent substance use, thereby minimizing effect of underreporting on rates of prenatal 
drug use. Consequently, study findings offer new information about the sensitivity and 
specificity of two commonly-used screening tools for predicting prenatal drug use (DAST and 
Drug CAGE). Results yielded only moderate sensitivity for both screeners, suggesting many at-
risk women would have fallen through the cracks if screening was limited to such tools.  
Despite practices to facilitate self-reported drug use, pregnant women in this sample still 
underreported their drug use (69% tested positive by UDS, but denied past month use). Results 
suggest that under the best of circumstances, every two out of three women who screened 
positive by UDS would not, in clinical practice, come to attention of their healthcare providers 
via current screening practices (i.e., direct self-report). This finding is consistent with the results 
of Grekin and colleagues (2010), who found that 80% of the sample who had a positive urine 
and/or hair screen denied drug use. In comparing these two studies, there is also evidence to 
support some differences in the degree of disclosure of drug use and related consequences 
between these two samples (i.e., differences in endorsement rates of DAST items, greater legal 
consequences associated with testing positive postpartum versus testing positive prenatally in an 
outpatient setting). Regardless, screening efforts that rely solely on self-report to identify 
prenatal drug use are likely to miss a significant proportion of drug users even when ideal 
conditions for disclosure are present. Not surprisingly given underreporting, indirect screening 
measures emerged as the best approach to identify recent prenatal drug use.  
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The merit of indirect screening. The WIDUS, WIDUS+abortion and WIDUS-P were 
the most sensitive screening tools, identifying the greatest proportion of drug users. While 
additional research is needed to further examine the predictive validity of these different 
screeners, collectively, these findings provide a promising start to better identification of prenatal 
drug use. Interestingly, the WIDUS, which was developed and validated on postpartum women 
in Detroit, performed well in identifying pregnant drug users in this sample. This supports 
generalizability of the WIDUS from postpartum women to other samples of urban pregnant 
women. Additionally, the results of this study suggest that adding the abortion item may increase 
the predictive validity of the WIDUS. Although this improvement may be small, it may lead to 
better identification of prenatal drug use across time. An important consideration to adding this 
item is that women may feel uncomfortable answering this question. While the item is indirect 
(i.e., it does not reference drugs) and may add unique variance, it may threaten the innocuous 
intention of an indirect measure. Conversely, pregnant women may not view this question as 
offensive because it is asked within an OB setting where questions about their reproductive 
health are appropriate and expected. Future studies are needed to support the incremental validity 
of the abortion item to the WIDUS and also to determine OB patients’ acceptability of including 
the abortion item in a brief measure.  
The WIDUS-P, developed and validated on this sample was the most sensitive measure 
of prenatal drug use. While the WIDUS-P performed well as a prenatal drug use screener in this 
sample, it is important to take into consideration the generalizability of this measure given the 
shape of its ROC curve. For the ROC curves of both the training and validation samples, changes 
in cut-off scores at certain levels were associated with dramatic changes in sensitivity and 
specificity. For example, within the validation sample, sensitivity decreased from .90 to .50 when 
the cut-off score was increased from three to four. In this sample, the optimal cut-off score was 
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three. A higher cut-off score results in a significant compromise in sensitivity. However, given 
that cut-off scores are very sample dependent, these drastic changes in sensitivity and specificity 
could be problematic when the WIDUS-P is used in different samples. The WIDUS-P may not 
be as useful for identifying prenatal drug use when applied to different samples of pregnant 
women (e.g., private practice settings, rural OB clinics). 
Clearly, further research is needed to evaluate the predictive validity of each of these 
three measures. At present, there is too much variability to make definitive statements across 
studies and measures. Next steps include evaluating these measures in different samples of 
pregnant women (e.g., women who have recently delivered at VCU, other urban OB clinics), 
extending the window of drug detection by including hair analysis, and utilizing different 
statistical techniques in both the development (i.e., item reduction process) and validation phase 
of measure development. In this study, we chose to develop the WIDUS-P on a sample of 131 
participants and then validate it on the remaining 100 participants. An alternative approach 
would have been to use CART or LOO (leave one out) cross-validation. Different statistical 
processes may identify additional items that contribute unique variance not captured in the 
WIDUS-P items. Similarly, they may also confirm the predictive validity of the WIDUS-P items. 
Further investigation of indirect screening, based on the present findings, could also be 
extended to examine the combination of direct and indirect screening. Asking participants 
directly about their drug use in the past month had high specificity, but low sensitivity. On the 
other hand, the WIDUS-P had high sensitivity and lower specificity. Combining these 
approaches could lead to an ideal combination of sensitivity and specificity. Concurrent 
screening (i.e., in a single measure, asking the WIDUS-P items first and then question about past 
month use) is preferable to sequential screening (i.e., administering the WIDUS-P only if past 
month drug use is denied) because women could become defensive when asked directly about 
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recent drug use and consequently, minimize subsequent report of any behaviors or life 
experiences.  
Indirect screening is a stark contrast to current screening approaches which are either 
non-existent or involve direct mention of drug use and its consequences. Compared to these 
methods, an indirect approach offers more effective screening. As supported by the present 
findings, indirect tools are more sensitive measures of prenatal drug use than direct methods: 
they identify a greater proportion of recent drug users. This is of paramount importance because 
in order for prenatal interventions to be effective, screening tools must first accurately identify 
at-risk women. From a public health perspective, if a significant proportion of women who use 
drugs prenatally are missed, the intervention has less of an impact at the population level. 
Interventions are also less effective when they are not easily applied to real world settings 
(Smeeth & Ebrahim, 2000). The innocuous nature of indirect screening enables this approach to 
be easily implemented into regular clinic practice. OB clinic staff will likely be more receptive to 
using a screener which does not directly address drug use than using a face-valid screener such 
as the DAST or Drug CAGE. Additionally, a computerized screening tool offers both time and 
cost savings for providers, as well as greater translational value, as it can be easily integrated into 
standard care in a variety of health settings. Taken together, an indirect, computerized screener, 
such as the ones reported in this study, can allow practitioners to screen more pregnant women 
and better identify those at risk for drug use. 
Limitations 
 One of the main limitations of this study was the way in which participants’ drug status 
was defined. Pregnant women were considered “drug positive” if their urine drug screen was 
positive for methamphetamines, cocaine, marijuana, barbiturates, MDMA and/or PCP. Thus, 
biological report was based solely on UDS and not both hair and urine testing, as was collected 
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in Dr. Ondersma’s research. This method of biological testing was chosen for several reasons. 
Urine samples are relatively easy to collect as OB clinic patients are accustomed to providing 
them as part of their routine prenatal care and this method is less invasive than collecting hair or 
blood samples. In addition, urinalysis costs less than other methods (e.g., hair analysis costs 
around $75/sample). Furthermore, despite urinalysis’ short window of detection for most drugs, 
this method is appropriate because one of the most common drugs of abuse among this 
population is marijuana (Saitz, Svikis, et al., 2006), which has a much longer window of 
detection than other drugs (Wolff et al., 1999). Finally, given that the prenatal clinic does not 
ever screen for illicit drugs and that all study information was collected anonymously, 
contamination of urine samples by participants was considered unlikely because there was no 
specific motivation for women to reduce or eliminate use prior to their prenatal visit. Although 
both urine and hair assay were utilized in Dr. Ondersma’s study with postpartum women, for the 
aforementioned reasons, urinalysis was selected for use in the current study. 
As a result of using only urinalysis as the gold standard criterion, the window of detection 
in this study was shorter than if both methods had been utilized (i.e., the full period of pregnancy 
was not captured by toxicology screens). Consequently, women who used drugs during 
pregnancy but outside of the window of detection for urinalysis were “missed.”  For example, a 
participant in her third trimester could have used marijuana during her first trimester but not have 
tested positive on the UDS. Additionally, because it was unknown whether women were using 
benzodiazepines, methadone, opiates and/or oxycodone legally (i.e., with a prescription), this 
data was omitted from their drug status. Participants’ medical records could not be accessed to 
rule-out prenatal prescription drug use because the study was anonymous. In this manner, 
anonymity was both a strength and limitation of the study. Given these limitations, it is likely 
that the “true” rate of prenatal drug use is even higher than the rate documented (15.6%). It is 
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possible that this underestimation of drug use affected which indirect items were selected and the 
predictive validity of the various direct and indirect screening methods examined.  
 Another limitation concerns the issue of generalizability. The study was conducted with 
pregnant women who were predominately African American, low-income, and young. From a 
health disparities perspective, this is an important at-risk group to study; however, results may 
not generalize well to other populations. In addition, the primary drug used by women who 
tested positive was marijuana. Thus, it is unknown how well the predictive validity of indirect 
screeners developed in this study will apply to other classes of drugs.  
Final Thoughts 
 Current prenatal drug use screening practices are insufficient. Indirect screening is a 
promising approach to better identify drug use in pregnant women, regardless of their 
willingness to disclose such use. Although changes to prenatal drug use screening addresses only 
one part of a complex problem, it is an important foundation upon which to impact greater 
numbers of at-risk women and build more effective interventions.  
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Appendix 1 
 
Preliminary Literature Review of Correlates of Current Drug Use:  Behavioral, Medical, 
Psychological, Experiential, and Demographic  
Borrowed from Dr. Steven Ondersma 
 
 
 
 
CORRELATES REFERENCES 
Behavioral Correlates  
Suicide attempt 
(Allgulander, Allebeck, Przybeck, & Rice, 1992; Glavak, 
Kuterovac-Jagodic, & Sakoman, 2003; Schaar & Ojehagan, 
2001) 
Associating with drug-using 
peers 
Lehman, Barrett, & Simpson, 1990; McCuller, Sussman, 
Dent, & Teran, 2001; Newcomb, 1997; Newcomb & Felix-
Ortiz, 1992) 
Gambling, lotto, etc. (Lesieur, Blume, & Zoppa, 1986; Ramirez, McCormick, Russo, & Taber, 1983) 
Involvement in faith (Adlaf & Smart, 1985; Newcomb & Felix-Ortiz, 1992; Reisinger et al., CPDD, 2005) 
Smoking 
(Richter, Ahluwalia, Mosier, Nazir, & Ahluwalia, 2002; 
Newcomb, Galaif, & Locke, 2001; Substance Abuse and 
Mental Health Services Administration, 2001; Svikis, 
Henningfield, Gazaway, Huggins, Sosnow, Hranicka, 
Harrow, & Pickens, 1997) 
Problem alcohol use 
(Carlson, Falck, Wang, Siegal, & Rahman, 1999; Sanz 
Aliaga, Sabater Pons, Alfonso Sanchez, Carbajal de Lara, & 
Sancho Izquierdo, 2000; Schubiner, et al., 2000; Substance 
Abuse and Mental Health Services Administration, 2001) 
Criminality 
(Corty & Ball, 1987; Kane & DiBartolo, 2002; Kosten, 
Gawin, Rounsaville, & Kleber, 1986; Substance Abuse and 
Mental Health Services Administration, 2001; Villalobos, 
Cropsey, Weaver, & Stitzer, CPDD, 2005) 
Emergency room use (Hoffman & Goldfrank, 1990) 
Lifetime drug use (Schifano, DiFuria, Forza, Minicuci, & Bricolo, 1998) 
Impaired occupational 
functioning 
(Kirisci, Vanyukov, Dunn, & Tarter, 2002; McCusker, 
Bigelow, Frost, Garfield, Hindin, Vickers-Lahti, & Lewis, 
1997; Newcomb, 1997) 
Impaired academic 
functioning 
(Ong, 1987; Kirisci, Vanyukov, Dunn, & Tarter, 2002; 
Newcomb, 1997; Schubiner, Tzelepis, Milberger, Lockhart, 
Kruger, Kelley, & Schoener, 2000) 
Impaired social functioning (Kirisci, Vanyukov, Dunn, & Tarter, 2002; Lende & Smith, 
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2002; Mowbray, Ribisl, Solomon, Luke, & Kewson, 1997) 
Age at first cigarette, drink 
(McGue, Iacono, Legrand, Malone & Elkins, 2001; 
Schubiner, Tzelepis, Milberger, Lockhart, Kruger, Kelley, & 
Schoener, 2000; Word & Bowser, 1997; Young, 1992) 
Prenatal care (Eriksson, Larsson, & Zetterstrom, 1979) 
Caffeine intake (Fillmore, 2003) 
   
Medical Correlates  
Chronic illness (Cardoso & Jankovic, 1993; Rosenblum, Joseph, Fong, Kipnis, Cleland, & Portenoy, 2003) 
Chronic pain (Longo, Parran, Johnson, & Kinsey, 2001; Rosenblum, Joseph, Fong, Kipnis, Cleland, & Portenoy, 2003) 
Any sexually trans. dis. 
(French, Mauskopf, Teague, & Roland, 1996; Hwang, Ross, 
Zack, Bull, Rickman, & Holleman, 2000; Kreek, 1996; Word 
& Bowser, 1997) 
Pneumonia  
(French, Mauskopf, Teague, & Roland, 1996; de Gaetano, 
Bertagnolio, Tumbarello, Tacconelli, Cataldo, Longo, & 
Cauda, 2000; Gotway, Marder, Hanks, Leung, Dawn, Gean, 
Reddy, Araoz, & Webb, 2002) 
Liver disease (Novick, Reagan Croxson, Gelb, Stenger, & Kreek, 1997; Tong & el-Farra, 1996) 
Hepatitis 
(Brown, Hickson, Ajuluchukwu, & Bailey, 1993; French, 
Mauskopf, Teague, & Roland, 1996; Hwang, Ross, Zack, 
Bull, Rickman, & Holleman, 2000; Kreek, 1996; Schafer, 
Boetsch, & Laakmann, 2000) 
HIV / HIV risk 
(Carlson, Falck, Wang, Siegal, & Rahman, 1999; Hoffman & 
Goldfrank, 1990; Hwang, Ross, Zack, Bull, Rickman, & 
Holleman, 2000; Kreek, 1996; Nnadi, Better, Tate, Herning, 
& Cadet, 2002; Singh, Prasad, & Mohanty, 1999; Specter, 
1994;  Svikis, Gorenstein, Paluzzi, & Fingerhood, 1998; 
Word & Bowser, 1997) 
Tuberculosis 
(Bernado, 1991; Curtis, Friedman, Neaigus, Jose, Goldstein, 
& Des Jarlais, 1994; Foley, Ehr, Raza, & Devlin, 1995; 
French, Mauskopf, Teague, & Roland, 1996; Taubes, 
Galanter, Dernatis, & Westreich, 1998) 
Vascular problems (Perlman & Thordarson, 1999; Roszler, McCarroll, Donovan, Rashid, & Kling, 1989) 
  
Psychological Correlates  
Depression 
(Biederman, Faraone, Wozniak, & Monuteaux, 2000; 
Coelho, Rangel, Ramos, Martins, Prata, & Barros, 2000; 
Goldberg, Singer, & Garno, 2001; Majewska, 1996; 
McCuller, Sussman, Dent, & Teran, 2001; Roberts, 2000; 
Schaar & Ojehagan, 2001; Sussman, Dent, & Galaif, 1997) 
Anxiety (McCuller, Sussman, Dent, & Teran, 2001; Nnadi, Better, 
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Tate, Herning, & Cadet, 2002; Word & Bowser, 1997) 
PTSD (Clark, Masson, Delucci, Hall, & Sees, 2001; Majewska, 1996) 
Antisocial PD (Henderson & Galen, 2003; Kosten, Gawin, Rounsaville, & Kleber, 1986; Newcomb, 1997) 
Conduct disorder in childhood/ 
neurobehavioral disinhibition 
(Biederman, Faraone, Wozniak, & Monuteaux, 2000; 
Majewska, 1996; Schubiner, Tzelepis, Milberger, Lockhart, 
Kruger, Kelley, & Schoener, 2000; Tarter, Kirisci, Mezzich, 
Cornelius, Pajer, Vanyukov, Garner, Blackson, & Clark, 
2003) 
Mental disorders in general 
(Batki, 1990; Kirisci, Vanyukov, Dunn, & Tarter, 2002; 
Mason, Kocsis, Melia, Khuri, Sweeney, Wells, Borg, 
Millman, & Kreek, 1998; Newcomb, 1997; Schaar & 
Ojehagan, 2001; Schubiner, Tzelepis, Milberger, Lockhart, 
Kruger, Kelley, & Schoener, 2000; Tidey, Mehl-Madrona, 
Higgins, & Badger, 1998) 
Perceived stress (Gordon, 2002; Hoffmann & Cerbone, 2002; Kreek, 1996; McMahon, 2001; Sinha, 2001) 
Perceived social support (McMahon, 2001; Schafer, Schnack, & Soyka, 2000; Word & Bowser, 1997) 
Feelings of persecution (Nnadi, Better, Tate, Herning, & Cadet, 2002) 
Negative affectivity (Henderson & Galen, 2003; Stacy, Newcomb, & Bentler, 1993) 
Liberal beliefs regarding drugs (Newcomb, 1997) 
Expectancies (Boyd, 1998; Henderson & Galen, 2003; Newcomb, 1997) 
Regret / guilt 
(Gerra, Fertonani, Zaimovic, Rota-Graziosi, Avanzini, 
Caccavari, Delsignore, & Lucchini, 1995; Goldstein, Powers, 
McCusker, Mundt, Lewis, & Bigelow, 1996) 
Boredom 
(Binion, Miller, Beauvais, & Oetting, 1988; Mintz, O’Brien, 
& Pomerantz, 1979; O’Connor, Berry, Morrison, & Brown, 
1995; Stacy, Newcomb, & Bentler, 1993; Yeh, Chen, & Sim, 
1995) 
Impulsivity 
(Allen, Moeller, Rhoades, & Cherek, 1998; Coffey, 
Gudleski, & Saladin, 2003; Goldberg, Singer, & Garno, 
2001; Jentsch & Taylor, 1999; Sarramon, Verdoux, Schmitt, 
& Bourgeois, 1999) 
Promiscuity (Carlson & Seigal, 1991; Roberts, Wechsberg, Zule, & Burroughs, 2003) 
Risk-taking (Hwang, Ross, Zack, Bull, Rickman, & Holleman, 2000; Sawrie, Kabat, Dietz, Greene, Arredondo, & Mann, 1996) 
Sensation-seeking 
Jaffe & Archer, 1987; Newcomb, 1997; Sarramon, Verdoux, 
Schmitt, & Bourgeois, 1999; Stacy, Newcomb, & Bentler, 
1993; Zuckerman & Neeb, 1979) 
Perceived use by others (Newcomb & Felix-Ortiz, 1992 
  
Demographic Correlates  
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Age (Newcomb, 1997; Substance Abuse and Mental Health Services Administration, 2001) 
Marital status (Horowitz & White, 1991; Reisinger et al., CPDD, 2005; Schaar & Ojehagan, 2001) 
Employment status 
(Ong, 1987; Substance Abuse and Mental Health Services 
Administration, 2001) (Schaar & Ojehagan, 2001; Reisinger, 
Dowling, Ensminger, & Chilcoat, 2005) 
Educational attainment (Newcomb, 1997; Ong, 1987; Substance Abuse and Mental Health Services Administration, 2001) 
Financial status (Schaar & Ojehagan, 2001) 
Family history of addiction 
(Compton, Cottler, Ridenour, Ben-Abdallah, & Spitznagal, 
2002; Glavak, Kuterovac-Jagodic, & Sakoman, 2003; 
Hoffmann & Cerbone, 2002; Lehman, Barrett, & Simpson, 
1990; Rounsaville, Kosten, Weisman, Prusoff, Pauls, Anton, 
& Merikangas, 1991) 
Receipt of public assistance (NIDA National Pregnancy and Health Survey, 1996) 
Culture, race 
(Bowser & Bilal, 2001; Boyd, 1998; Glavak, Kuterovac-
Jagodic, & Sakoman, 2003; McCuller, Sussman, Dent, & 
Teran, 2001; NIDA National Pregnancy and Health Survey, 
1996; Kosten, Gawin, Rounsaville, & Kleber, 1986; Smith, 
Buxton, Bilal, & Seymour, 1993) 
  
Experiential Correlates  
Child sexual abuse 
(Cohen & Densen-Gerber, 1982; Hoffman & Goldfrank, 
1990; Kane & DiBartolo, 2002; Schafer, Schnack, & Soyka, 
2000) 
Child physical abuse 
(Cohen & Densen-Gerber, 1982; Dube, Felitti, Dong, 
Chapman, Giles, & Anda, 2003; Kane & DiBartolo, 2002; 
Schafer, Schnack, & Soyka, 2000) 
Child neglect (Cohen & Densen-Gerber, 1982; Hoffman & Goldfrank, 1990) 
Domestic violence (Cohen & Densen-Gerber, 1982; Goldstein et al., 1996) 
Injury (Rothstein, Levy, Fecher, Gordon, & Bauman, 1992) 
Other interpersonal 
victimization (Boyd, 1998; Schafer, Schnack, & Soyka, 2000) 
Other trauma (Dube, Felitti, Dong, Chapman, Giles, & Anda, 2003) 
Blackouts (Buelow & Buelow, 1995) 
Home shifts (Larsson, Eriksson, Zetterstrom, 1979; Stein, Newcomb, & Bentler, 1987) 
Conflict within family 
(Dube, Felitti, Dong, Chapman, Giles, & Anda, 2003; 
Glavak, Kuterovac-Jagodic, & Sakoman, 2003; McCuller et 
al., 2001; Newcomb, 1997; Yeh, Chen, & Sim, 1995) 
Poor/limited/ inconsistent 
consequences for misbehavior (Newcomb, 1997; Yeh, Chen, & Sim, 1995) 
Violence exposure in general (Inciardi & Surratt, 1998) 
Running away in adolescence (Goldstein, Powers, McCusker, Mundt, Lewis, & Bigelow, 
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1996; Morey & Friedman, 1993) 
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Appendix B 
 
 
Recruitment Script 
 
 
 
 
Part A. 
“Hello, my name is ________ and I am part of the AWHARE Women’s Health Research team 
here at VCU. We are conducting a project with pregnant women at Nelson Clinic. May I talk to 
you for a few minutes?” 
 
“First, can I ask if you are at least 18 years old?” 
 IF “NO”: “Thank you for your time. At this point, you do not qualify for this study.” 
 
“And, may I ask if you are here today for a RETURN prenatal appointment?” 
 IF “NO”: “Thank you for your time. At this point, you do not qualify for this study.” 
 
“I am working on a research project that focuses on developing a questionnaire that will help 
identify women who may need help. The project is ANONYMOUS- it will not require you to tell 
me your name. It involves a questionnaire that will ask you about your health, activities and 
habits, childhood and teenage experiences, life experiences, thoughts, and feelings. It will take 
about 30 minutes to complete after your OB appointment today and you will be given up to $40 
in gift cards for your time.” 
 
“Are you interested in participating today?” 
IF “YES”: “Ok, well I will wait for you in the waiting room until you finish your 
appointment. Afterwards, we can go to our research offices across from Ultrasound and I 
can tell you more about the project and then you can complete the study if you are 
interested. Here is a reminder card for the study.”   
 
RA will give the woman a reminder card. 
 
After patient’s appointment, RA will take her to office space, collect the reminder card, and read 
Information Sheet #1 to the patient. 
 
Complete Phase 1. 
 
Part B.  
RA will give participant her gift card and then read Information Sheet #2. 
 
“Are you interested in participating in Phase 2?” 
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IF “YES”: “Ok, I will show you where the restroom is. Once you are inside the restroom, 
you’ll see a metal cabinet. Inside the cabinet is a urine sample cup. Please fill the cup 
about 1.5 inches full of urine and then place it back in the cabinet when you are done. I’ll 
be waiting out here after you have finished.”  
 
Complete Phase 2: RA shows the patient to the restroom. After the patient has provided a sample 
and left the restroom, the RA will give her Information Sheet #3, give her a gift card, and thank 
her for her participation. 
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Appendix C 
 
 
WIDUS-P Development Version 
 
 
 
 
“Basic Information About Me.” 
Here are some questions about you...your living, and work 
situation right now...Okay, here we go... 
 
1. How old are you?                                                                                   a) 18-21 
b) 22-25 
c) 26-29 
d) 30-33 
e) 34-37 
f) ≥ 38 
2. What is your ethnic background? a) American Indian or 
Alaska Native 
b) Black or African 
American 
c) Hispanic or Latino 
d) Native Hawaiian or 
other Pacific Islander 
e) Asian 
f) White 
g) Middle Eastern 
American (Assyrian, 
Lebanese, Kurdish, Arab, 
Aremaic, etc) 
h) More than one race 
i) Unknown 
3.  I am currently married. (5) True False 
4. I graduated from high school or completed my GED. (6) True False 
5. I am currently working 20 hours or more per week. (7-edited) True False 
6. I currently have health insurance through an employer, either mine True False 
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or a family member’s (do not include Virginia Premier). (8 edited) 
7.  I currently receive some form of public assistance, such as food 
stamps, WIC, Medicaid, SSI, or TANF. (9)  
True False 
“My Health.” 
Here are some True and False questions about your health... 
 
8. At least once in my life, I have been diagnosed with a sexually 
transmitted disease, such as gonorrhea, Chlamydia, Herpes, 
syphilis, HIV, or any other sexually transmitted infection. (12) 
True False 
9. I have been diagnosed with Hepatitis C. (13) True False 
10. I almost always use condoms during sex. (14) True False 
11. I often eat fast food and/or junk food. (15) True False 
12. I have been treated at an emergency room in the past year. (16) True False 
13. I have missing teeth. (17) True False 
14. In the past year, I have been bothered by pain in my teeth or mouth. 
(18) 
True False 
“My Activities and Habits.” 
We’d like to know just a little about what you do, and some of your 
habits... We ask everybody the same questions...you may or 
may not do these things... Remember, no one will know your 
answer... 
 
15. I have smoked at least 100 cigarettes in my entire life. (19) True False 
16. I was a daily smoker during the year before I became pregnant. (20) True False 
17. I smoked at least one cigarette the week before I learned I was 
pregnant. (21-revised) 
True False 
18. I’m often around second hand cigarette smoke. (25) True False 
19. Most of my friends smoke cigarettes. (26) True False 
20. At least two of my closest friends use marijuana. (27) True False 
21. Most of my friends think marijuana is no big deal. (29) True False 
22. I have at least one caffeinated beverage (for example, caffeinated 
soda, coffee, or  energy drink) every day. (31-revised) 
True False 
 
“My Childhood and Teenage Experiences.” 
We’d like to ask you about some things that you, may or may 
not have experienced in your childhood and teenage 
years...you may or may not have seen similar questions 
before, but they are different because we are asking about 
your childhood or teenage years... Please answer True or 
False on each statement...let's go... 
 
23. When I was a child, I saw adults in my home physically hurting 
each other.  (34) 
True False 
24. When I was a child, I saw someone get stabbed, shot, or seriously 
beaten. (35) 
True False 
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25. When I was a child, an adult hit me hard enough to cause bleeding,  
bruises, or welts. (36) 
True False 
26. When I was a child, an adult touched my private parts in a sexual 
manner, or got me to touch their private parts in a sexual manner. 
(37) 
True False 
27.  When I was a child, I saw people using drugs in my home. (40) True False 
28. Since my sixteenth birthday, I have had fractures or dislocations to 
my bones or joints. (42) 
True False 
29. Since my sixteenth birthday, I have injured my head. (44)   True False 
30. Since my sixteenth birthday, I have been injured in an assault or 
fight (not counting injuries during sports). (45)   
True False 
 
 
“My Lifetime Experiences.” 
We'd like to ask you about some things that you may or may 
not have experienced in your lifetime...you may or may not 
have seen similar questions before, but they are different 
because we are asking about your whole life. Please answer 
True or False on each statement... 
  
31. There have been times in my life, for at least two weeks straight, 
where I felt completely worthless. (47) 
True False 
32. There have been times in my life, for at least two weeks straight, 
where I felt completely hopeless about things. (48) 
True False 
33. There have been times in my life, for at least two weeks straight, 
where I felt so down or depressed that nothing could cheer me up. 
(49) 
True False 
34. There have been times in my life, for at least two weeks straight, 
where it felt like everything was an effort. (50) 
True False 
35. As an adult, I have been badly beaten up at least once. (53) True False 
36. As an adult, I have seen somebody get stabbed, shot, or seriously 
beaten.   (54) 
True False 
37. One or more of my biological parents have had a problem with 
drugs or alcohol. (56) 
True False 
38. One or more of brothers or sisters has had a problem with drugs or 
alcohol. (57) 
True False 
39. I have been abandoned by someone I love more than most people 
have. (60) 
True False 
40. I have been in trouble with the police. (61) True False 
41. In my lifetime, I have been hit, slapped,  kicked or otherwise 
physically hurt by someone. 
True False 
42. There have been times in my life I have not felt safe around my 
current partner or past partner. 
True  False 
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“My Recent Experiences.” 
We'd like to ask you about some things that you may or may 
not have experienced recently...you may or may not have seen 
similar questions before, but they are different because we 
are asking ONLY about recent experiences. Please answer 
True or False on each statement... 
  
43. Within the last year, I have been hit, slapped, kicked or otherwise 
physically hurt by someone. 
True False 
44. During my current pregnancy, I have been hit, slapped, kicked, or 
otherwise physically hurt by someone 
True False 
45. In the past year, I’ve gone hungry because I didn’t have enough 
money to buy food. 
True False 
46. It’s hard to get places because of transportation. True False 
47. In the past 12 months, I’ve worried about my housing situation. True False 
48. I often move from place to place. True False 
 
 
“My Personality, Attitudes, and Feelings.” 
We would like to ask you some True or False questions about 
you, your personality, attitudes, and feelings...everybody's 
answers are different... Some questions may or may not make 
you feel uncomfortable...so, do your best to answer the 
questions... Remember that nobody will know your answers... 
This section is the longest one, it should take about 5 minutes. 
  
49. In the past year, the police have been called to my home because of 
a fight or argument. (67) 
True False 
50. Things have usually gone against me in life. (69) True False 
51. I get mad easily and feel a need to blow off some steam. (70) True False 
52. Some of my immediate family members are pretty violent. (71) True False 
53. I feel overwhelmed by my life and my problems. (75) True False 
54. I get bored easily. (79) True False 
55. I live life on the edge. (80) True False 
56. I have conflict with people in authority, like teachers, supervisors, 
and the police. (81) 
True False 
57. I experience “flashbacks” of bad things that have happened to me. 
(82) 
True False 
58. At least one person in my immediate family (parent, brother, or 
sister) has had problems with depression. (83) 
True False 
59. I sometimes do really harmful things to myself. (84) True False 
60. In elementary school, I often got into trouble with teachers or the 
principal because of my behavior (fighting, talking in class, or 
coming to class late). (85) 
True False 
93 
 
61. I am easily upset about things. (86) True False 
62. When I was younger than 13 years old, I often stayed out past 
midnight. (87) 
True False 
63. I have seen or experienced worse things than most other people 
have. (90) 
True False 
64. Over the past month, I have felt down, depressed, or hopeless. (91) True False 
65. Drugs are everywhere in my neighborhood. (94) True False 
66. I often have trouble sleeping (not counting during pregnancy). (95) True False 
67. I feel very overwhelmed when thinking about taking care of a new 
baby. (96) 
True False 
68. I have repeated and disturbing memories of a stressful thing that 
happened to me. (99) 
True False 
69. I lose my temper very easily. (100) True False 
70. In the past, I have told someone that I was going to hurt myself. 
(105) 
True False 
71. I often feel empty inside. (108) True False 
72. In the past, I have attempted to hurt myself. (114) True False 
“My current pregnancy” 
So, now we’d like to ask you some questions related to your 
pregnancy. 
 
  
73. How many weeks pregnant are you? 1-42 
74. How many weeks pregnant were you when you first thought you 
might be pregnant? 
1-42 
75. How many weeks pregnant were you when attended your 1st OB 
appointment. 
1-42 
76. Thinking back to just before you got pregnant, how did you feel 
about becoming pregnant? 
a) I wanted to be pregnant 
sooner. 
b) I wanted to be pregnant 
then. 
c) I wanted to be pregnant 
later. 
d) I didn’t want to be 
pregnant then or at any 
time in the future. 
e) I don’t know. 
77. How many times have you been pregnant, including the current 
pregnancy? 
This is my first 
pregnancy, 1,2,3,4,5, 6, 7, 
8 or more 
78. How many of these pregnancies ended in the birth of a live baby? None, 1,2,3,4,5, 6, 7, 8 or 
more 
79. Have you ever had a baby that died during birth or was stillborn? Yes No 
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80.  Have you ever had a pregnancy that ended during the first 4 
months (not including an abortion)? 
Yes No 
81. Have you ever had a pregnancy that ended after 4 months but 
before birth? 
Yes No 
82. Have you ever had an abortion? Yes No 
83. Are you currently in a relationship? a) Yes, with the father of 
my baby. 
b) Yes, with someone 
other than the father of my 
baby. 
c) No, I am not in a 
relationship. 
“The father of this baby” 
We’d like to know just a little about your relationship with 
the father of your baby and some of his habits... We ask 
everybody the same questions...you may or may not do these 
things... Remember, no one will know your answer... 
 
84.  Thinking about the amount of contact you’ve had with the father of 
this baby, which statement best fits you? 
a) I’ve had contact with 
the father of this baby in 
the past and right now. 
b) I’ve had contact with 
the father of this baby in 
the past but not right now. 
c) I don’t know the father 
of this baby that well. 
85. The father of this baby currently smokes cigarettes. True False 
86. The father of my baby thinks marijuana is no big deal. True False 
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Appendix D 
 
 
Information Sheet #1 
 
 
 
 
ANONYMOUS SURVEY 
Consent Information Sheet 
 
Are you pregnant?  
Part One 
 We would like your help in developing a questionnaire that will help identify women 
who may need help. This survey is for pregnant women who are 18 years of age and 
older and who are coming to Nelson Clinic for prenatal care.   
 
 If you choose to participate, we’ll ask you to complete a questionnaire on the computer 
while you wait to be called back for your appointment. This survey will take about 20 
minutes and will ask you about many different things about yourself, including your 
background information, health, activities and habits, childhood and teenage experiences, 
lifetime experiences, personality, attitudes, thoughts, and feelings.   
 
 There are very few risks to you for participating. You may find some questions easy to 
answer and others may be harder to answer. Please be as honest as possible.  If you get 
uncomfortable and don’t want to answer a question, that is ok. If you start the survey and 
don’t want to finish that is ok too.  
 
 This questionnaire is ANONYMOUS, meaning we are not asking you for your name so 
we won’t be connecting your name with your answers. 
 
 Your participation is VOLUNTARY and whether you choose to participate or not will 
not affect your care at Nelson Clinic.  
 
 For completing the survey, we will give you a $20 gift certificate. 
 
Part Two:  We’ll tell you more about part two after you have completed Part One. 
 
This project is a VCU-sponsored research project. If you have any questions about the project, 
please call Courtney Smith at (804)-628-2553 or Dr. Svikis at (804)-827-1184. Thank you for 
your help! We appreciate your input and feedback. 
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If you have any questions about your rights as a participant in this study, you may contact: Office 
for Research, Virginia Commonwealth University, 800 E. Leigh Street, Suite 113, P.O. Box 
980568, Richmond, VA, 23298. Telephone: 804-827-2157. 
 
***OPTIONAL: You can sign this consent form if you want to do so. Your signature is not 
required to participate in the study. 
 
 
CONSENT 
I have been given the chance to read this consent form. I understand the information about this 
study. Questions that I wanted to ask about the study have been answered. My signature says that 
I am willing to participate in this study. 
 
 
Participant name print  Participant signature     Date 
 
 
Witness name printed   Witness signature    Date 
 
 
Name of person conducting   Signature     Date 
Informed Consent printed 
 
 
Investigator signature (if different from above) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Information Sheet #1
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Appendix E 
 
 
Information Sheet #2 
 
 
 
 
Thank you for participating in Part One!  Now, we’ll tell you about Part Two. 
 
Part Two: The second part of this project asks for your verbal permission to drug test your 
urine. If you agree to participate, the staff member will perform the test after you provide a 
sample for the study. They will test your urine in the bathroom without any clinic staff, doctors, 
or nurses present. After the testing is complete, they will immediately discard the results. Your 
results will not have your name on it and will NOT be shared with any staff, doctors, or nurses at 
Nelson Clinic. For your participation, you will be given a $20 gift card. Just like Part One, your 
participation is voluntary and will not affect your care at VCUHS.  
 
This project is a VCU-sponsored research project. If you have any questions about the project, 
please call Courtney Smith at (804)-628-2553 or Dr. Svikis at (804)-827-1184. Thank you for 
your help!  We appreciate your input and feedback. 
 
***OPTIONAL: You can sign this consent form if you want to do so. Your signature is not 
required to participate in the study. 
 
CONSENT 
I have been given the chance to read this consent form. I understand the information about this 
study. Questions that I wanted to ask about the study have been answered. My signature says that 
I am willing to participate in this study. 
 
 
Participant name print   Participant signature    Date 
 
Witness name printed   Witness signature    Date 
 
Name of person conducting   Signature     Date 
Informed Consent printed 
 
Investigator signature (if different from above) 
 
 
Information Sheet #2 
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Appendix F 
 
 
Information Sheet #3 
 
 
 
 
Thank you for participating in both Part One and Two of this project. Your help is greatly 
appreciated. We asked you about Part Two after you completed Part One because we wanted you 
to answer the questions as any pregnant woman attending prenatal care would do. That is, we did 
not want to influence your responses to Part 1. If you have any questions about the project, 
please call Courtney Smith at (804)-628-2553 or Dr. Svikis at (804)-827-1184. Again, thank you 
for your time! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Information Sheet #3 
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